WO2001043781A1 - Near infrared fluorescent contrast agent and fluorescence imaging - Google Patents
Near infrared fluorescent contrast agent and fluorescence imaging Download PDFInfo
- Publication number
- WO2001043781A1 WO2001043781A1 PCT/EP1999/009959 EP9909959W WO0143781A1 WO 2001043781 A1 WO2001043781 A1 WO 2001043781A1 EP 9909959 W EP9909959 W EP 9909959W WO 0143781 A1 WO0143781 A1 WO 0143781A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- contrast agent
- salt
- near infrared
- formula
- Prior art date
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 68
- 238000000799 fluorescence microscopy Methods 0.000 title abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 249
- 229910001868 water Inorganic materials 0.000 abstract description 64
- 125000000542 sulfonic acid group Chemical group 0.000 abstract description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 46
- 238000000034 method Methods 0.000 abstract description 22
- 230000005284 excitation Effects 0.000 abstract description 19
- 238000001514 detection method Methods 0.000 abstract description 6
- 230000005540 biological transmission Effects 0.000 abstract description 5
- 230000003902 lesion Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 153
- 239000011734 sodium Substances 0.000 description 98
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 57
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 50
- -1 porphyrin compound Chemical class 0.000 description 50
- 150000003839 salts Chemical class 0.000 description 48
- 125000000217 alkyl group Chemical group 0.000 description 38
- 239000013078 crystal Substances 0.000 description 35
- 159000000000 sodium salts Chemical group 0.000 description 35
- 239000000203 mixture Substances 0.000 description 28
- 238000001914 filtration Methods 0.000 description 22
- 0 C*(c1ccc(cc(*)cc2)c2c11)=C(***)C1(*)N(*)I Chemical compound C*(c1ccc(cc(*)cc2)c2c11)=C(***)C1(*)N(*)I 0.000 description 18
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 18
- 239000001632 sodium acetate Substances 0.000 description 18
- 235000017281 sodium acetate Nutrition 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 229940086542 triethylamine Drugs 0.000 description 16
- 125000000623 heterocyclic group Chemical group 0.000 description 15
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000007706 flame test Methods 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 11
- 238000003384 imaging method Methods 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000000862 absorption spectrum Methods 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 125000004964 sulfoalkyl group Chemical group 0.000 description 8
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical class [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002073 fluorescence micrograph Methods 0.000 description 6
- 238000010189 synthetic method Methods 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000005605 benzo group Chemical group 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000005110 aryl thio group Chemical group 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DRORSPJLYCDESA-UHFFFAOYSA-N 4,4-dimethylcyclohexene Chemical group CC1(C)CCC=CC1 DRORSPJLYCDESA-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 150000007524 organic acids Chemical group 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical class C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical class CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 1
- OQFSYHWITGFERZ-UHFFFAOYSA-N 2-bromoethanesulfonic acid Chemical compound OS(=O)(=O)CCBr OQFSYHWITGFERZ-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical compound N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 1
- KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- GAGTXGQOZJOFSZ-UHFFFAOYSA-N C[O](=C)(=C)#C[N]#C Chemical compound C[O](=C)(=C)#C[N]#C GAGTXGQOZJOFSZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 125000004436 sodium atom Chemical group 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
Definitions
- the present invention relates to a near infrared fluorescent contrast agent and fluorescence imaging using said contrast agent.
- One of the image diagnoses is fluorescence imaging (Lipspn R. L. et al., J. Natl. Cancer Inst, 26, 1-11 (1961 )).
- This method uses, as a contrast agent, a substance that emits fluorescence upon exposure to an excitation light having a specific wavelength.
- a body is exposed to an excitation light from outside the body and the fluorescence emitted from the fluorescent contrast agent in the body is detected.
- Such fluorescent contrast agent may be, for example, a porphyrin compound that accumulates in tumor and is used for photodynamic therapy (PDT), such as haematoporphyrin.
- PDT photodynamic therapy
- Other examples include photophrin and benzoporphyrin (see Lipspn R. L. et al., supra, Meng T. S. et al., SPIE, 1641, 90-98 (1992), WO 84/04665 and the like). These compounds are originally used for PDT and have phototoxicity, since this is what PDT requires. Consequently, these are not desirable diagnostic agents.
- Near infrared light shows high transmission through living tissues and can pass through a skull of about 10 cm in size. Because of this, it has been increasingly attracting attention in clinical medicine. For example, optical CT technique using optical transmission of medium has been drawing attention in the clinical field as a new technology. This is because near infrared light can pass through living body and can be used for monitoring oxygen concentration and circulation in the living body.
- Cyanine compounds emit fluorescence in the near infrared region.
- the fluorescence in this region can pass through living tissues and offers the potential for a fluorescent contrast agent.
- Various cyanine compounds have been developed in recent years and tried as fluorescent contrast agents (W096/17628, WP97/13490 and the like).
- an agent having sufficient solubility in water and safety to living body, as well as capability of distinguishing normal tissues from diseased tissues (selectivity for imaging target site) is not in existence.
- the inventive agent is low toxic and has a superior solubility in water. In addition, it emits fluorescence in a near infrared region that can pass through living tissues, and permits specific imaging of tumor and/or blood vessel.
- Another object of the present invention is to provide a method of fluorescence imaging using said near infrared fluorescent contrast agent.
- the present invention is predicated on the finding that introduction of three or more sulfonic acid groups into a cyanine dye compound results in the provision of a fluorescent contrast agent having a high solubility in water. It has been also found that a method of fluorescence imaging can be established when this contrast agent is used.
- the present invention provides the following.
- a near infrared fluorescent contrast agent comprising a compound having three or more sulfonic acid groups in a molecule, which is represented by the formula [I]
- R 1 and R 2 are the same or different and each is a substituted or unsubstituted alkyl; Z 1 and Z 2 are each nonmetallic atoms necessary for forming a substituted or unsubstituted condensed benzo ring or condensed naphtho ring; r is 0, 1 or 2; L 1 - L 7 are the same or different and each is a substituted or unsubstituted methine, provided that when r is 2, L 6 and L 7 that occur in duplicate are the same or different; and
- X and Y are the same or different and each is a group of the formula
- R 3 and R 4 are the same or different and each is substituted or unsubstituted alkyl, or a pharmaceutically acceptable salt thereof.
- R 1 , R 2 , L 1 - L 7 , X and Y are as defined above, and R 5 to R 16 are the same or different and each is a hydrogen atom, a sulfonic acid group, a carboxyl group, a hydroxyl group, an alkyl(sulfoalkyl)amino group, a bis(sulfoalkyl)amino group, a sulfoalkoxy group, a (sulfoalkyl)sulfonyl group or a (sulfoalkyl)aminosulfonyl group, exclusive of the groups of the following formulas
- R 1 and R 2 are each a lower alkyl having 1 to 5 carbon atoms substituted by a sulfonic acid
- R 19 and R 20 are lower alkyl having 1 to 5 carbon atoms and substituted by sulfonic acid group
- R 21 - R 28 are the same or different and each is hydrogen atom, sulfonic acid group, carboxyl group, hydroxyl group, alkyl(sulfoalkyl)amino group, bis(sulfoalkyl)amino group
- R 17 is hydrogen atom, sulfonic acid group, carboxyl group, hydroxyl group, alkyl(sulfoalkyl)amino group, bis(sulfoalkyl)amino group
- wh tom group necessary for forming a 5- or 6-membered ring and A is hydrogen atom or a monovalent group.
- a near infrared fluorescent contrast agent comprising the sodium salt of any of (9) to (19) above.
- a method of fluorescence imaging comprising introducing the near infrared fluorescent contrast agent of (1 ) above into a living body, exposing the body to an excitation light, and detecting near infrared fluorescence from the contrast agent.
- Figs. 1 to 4 are photographs showing fluorescence imaging at 24 hours after administration of the compound, wherein administered were A:ICG (5 mg/kg), B:NK-1967 (5 mg/kg), C.compound (29) (0.5 mg/kg) and D:compound (6) K salt (5 mg/kg).
- Fig. 5 is a photograph showing fluorescence imaging at 24 hours after administration of the compound, wherein administered was E:compound (31 ) (5 mg/kg).
- Figs. 6 to 9 are photographs showing fluorescence imaging at 20 seconds and 5 minutes after administration of the compound (5 mg/kg), wherein administered were A.ICG (20 seconds later), B.ICG (5 minutes later), C.compound (29) (20 seconds later) and D:compound (29) (5 minutes later).
- Fig. 10 is a graph showing the concentration of the compound in plasma at 0.5, 1 , 4 and 24 hours after administration of the compound, wherein the axis of ordinates is concentration ( ⁇ g/ml) of the compound in plasma at each time point.
- Fig. 11 is a chart showing the infrared absorption spectrum of compound (29).
- Fig. 12 is a chart showing the infrared absorption spectrum of compound (31 ).
- Fig. 13 is a chart showing the infrared absorption spectrum of compound (6).
- Fig. 14 is a chart showing the infrared absorption spectrum of compound (54).
- the near infrared fluorescent contrast agent in the present invention means a contrast agent that emits fluorescence in a near infrared region.
- the sulfonic acid group may mean sulfonate (-S0 3 " ) when said sulfonic acid group is used to form an inner salt.
- preferable X and Y are of the following formula
- R 3 and R 4 are the sa T me or different and each is substituted or unsubstituted alkyl.
- the alkyl of "substituted or unsubstituted alkyl" at R 1 , R 2 , R 3 and R 4 is preferably linear or branched lower alkyl having 1 to 5 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, 2-methylpropyl, 1 ,1-dimethylpropyl and the like.
- the substituent may be, for example, sulfonic acid group, carboxyl, hydroxy and the like.
- substituted alkyl examples include hydroxymethyl, 1- hydroxyethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 4- hydroxybutyl, carboxymethyl, carboxyethyl, carboxybutyl, sulfomethyl, 2- sulfoethyl, 3-sulfopropyl, 4-sulfobutyl and the like.
- R 1 and R 2 are lower alkyl having 1 to 5 carbon atoms that is substituted by sulfonic acid group (e.g., 2-sulfoethyl, 3-sulfopropyl, 4-sulfobutyl and the like), and R 3 and R 4 are unsubstituted lower alkyl having 1 to 5 carbon atoms (e.g., methyl, ethyl and the like).
- sulfonic acid group e.g., 2-sulfoethyl, 3-sulfopropyl, 4-sulfobutyl and the like
- R 3 and R 4 are unsubstituted lower alkyl having 1 to 5 carbon atoms (e.g., methyl, ethyl and the like).
- the unsubstituted lower alkyl having 1 to 5 carbon atoms at R 17 and R 18 is exemplified by those mentioned above with regard to the alkyl of "substituted or unsubstituted alkyl" at R 1 , R 2 , R 3 and R 4 .
- the alkyl group of the lower alkyl having 1 to 5 carbon atoms that is substituted by sulfonic acid group at R 19 and R 20 is exemplified by those mentioned above with regard to the alkyl of "substituted or unsubstituted alkyl" at R 1 , R 2 , R 3 and R 4 , and examples of the substituted lower alkyl having 1 to 5 carbon atoms include 2-sulfoethyl, 3-sulfopropyl and 4-sulfobutyl.
- alkyl moiety of alkyl(sulfoalkyl)amino group, bis(sulfoalkyl)amino group, sulfoalkoxy group, (sulfoalkyl)sulfonyl group and (sulfoalkyl)aminosulfonyl group at R 21 - R 28 is preferably a linear or branched lower alkyl having 1 to 5 carbon atoms, which is exemplified by those mentioned above with regard to the alkyl of "substituted or unsubstituted alkyl" at R 1 , R 2 , R 3 and R 4 .
- nonmetallic atoms necessary for forming a substituted or unsubstituted condensed benzo ring or condensed naphtho ring means a bonding group necessary for forming a condensed benzo ring or condensed naphtho ring, which is a group of the formula
- said bonding group may include a substituent.
- halogen atom e.g., fluorine atom, chlorine atom, bromine atom and iodine atom
- the substituent of the condensed benzo ring and condensed naphtho ring formed by the nonmetallic atoms at Z 1 and Z 2 is exemplified by sulfonic acid group, carboxyl, hydroxy, halogen atom (e.g., fluorine atom, chlorine atom, bromine atom and iodine atom), cyano, substituted amino (e.g., dimethylamino, diethylamino, ethyl 4-sulfobutylamino, di-(3-sulfopropyl)amino and the like), and substituted or unsubstituted alkyl as defined above, which is bonded to the ring directly or via a divalent bonding group.
- halogen atom e.g., fluorine atom, chlorine atom, bromine atom and iodine atom
- cyano substituted amino (e.g., dimethylamino, diethylamino,
- Preferable divalent bonding group may be, for example, -O-, -NHCO-, -NHS0 2 -, -NHCOO-, - NHCONH-, -COO-, -CO-, SO 2 -, and the like.
- the alkyl of substituted or unsubstituted alkyl that is bonded to the ring directly or via a divalent connection group is exemplified preferably by methyl, ethyl, propyl and butyl, and the substituent is preferably exemplified by sulfonic acid group, carboxyl and hydroxy.
- the substituent of methine at L 1 - L 7 is exemplified by substituted or unsubstituted alkyl (defined above), halogen atom (defined above), substituted or unsubstituted aryl, lower alkoxy and the like.
- the aryl of "substituted or unsubstituted aryl” is exemplified by phenyl, naphthyl and the like, preferably phenyl.
- Examples of the substituent include halogen atom (defined above, preferably chlorine atom) and the like.
- the substituted aryl includes, for example, 4-chlorophenyl and the like.
- the lower alkoxy is preferably linear or branched alkoxy having 1 to 6 carbon atoms, which is specifically methoxy, ethoxy, propoxy, butoxy, tert-butoxy, pentyloxy and the like, preferably methoxy and ethoxy.
- the substituents of methine at L 1 - L 7 may be bonded each other to form a ring containing three methine groups, and this ring may further form a condensed ring with a ring containing different methine group.
- the ring containing three methine groups that is formed by the bonding of the substituents of methine at L 1 - L 7 is exemplified by 4,4-dimethylcyclohexene ring and the like.
- the conjugated methine chain consisting of the groups of L 1 - L 7 , and having a ring is preferably the group of the formula (a):
- Z 3 denotes nonmetallic atoms necessary to form a 5- or 6-membered ring and A is hydrogen atom or a monovalent group.
- nonmetallic atoms necessary to form a 5- or 6-membered ring is exemplified by those mentioned above.
- - or 6-membered ring at Z 3 is exemplified by cyclopentene ring, cyclohexene ring, 4,4- dimethylcyclohexene ring and the like, with particular preference given to cyclopentene ring.
- the monovalent group represented by A includes, for example, substituted or unsubstituted alkyl (defined above), substituted or unsubstituted aryl (defined above), substituted or unsubstituted aralkyl, lower alkoxy (defined above), substituted amino which is optionally substituted, alkylcarbonyloxy (e.g., acetoxy), substituted or unsubstituted alkylthio, substituted or unsubstituted arylthio, cyano, nitro, halogen atom (defined above), and the like.
- aralkyl of the "substituted or unsubstituted aralkyl” is exemplified by benzyl, 2-phenylethyl, 1-phenylethyl, 3-phenylpropyl and the like, and the substituent may be sulfonic acid group, carboxyl, hydroxy, substituted or unsubstituted alkyl (defined above), alkoxy (defined above), halogen atom (defined above), and the like.
- the substituted amino of the "substituted amino which is optionally substituted” includes, for example, alkylamino (e.g., methylamino, ethylamino and the like), dialkylamino (dimethylamino, diethylamino and the like), diphenylamino, methylphenylamino, cyclic amino (e.g., morpholino, imidazolidino, ethoxycarbonylpiperadino and the like) and the like.
- the substituent with regard to the optional substitution of the "substituted amino which is optionally substituted” includes sulfonic acid group, carboxyl and the like.
- the alkylthio of the "substituted or unsubstituted alkylthio” may be, for example, methylthio, ethylthio and the like.
- substituent include sulfonic acid group, carboxyl and the like.
- arylthio of the "substituted or unsubstituted arylthio” is exemplified by phenylthio, naphthylthio and the like. Examples of the substituent include sulfonic acid group, carboxyl and the like.
- the monovalent group represented by A is preferably fluorine atom, chlorine atom, dialkylamino (preferably having 6 or less carbon atoms, and optionally forming a ring) or morpholino. This group particularly preferably has a sulfonic acid group.
- r is preferably 1.
- the pharmaceutically acceptable salt may be any as long as it forms a nontoxic salt with the compound of the formula [I].
- examples thereof include alkali metal salts such as sodium salt, potassium salt; salt of alkaline earth metal such as magnesium salt, calcium salt and the like; organic ammonium salt such as ammonium salt, triethyl ammonium salt, tributyl ammonium salt, pyridinium salt and the like; salt of amino acid such as lysine salt, arginine salt and the like.
- alkali metal salts such as sodium salt, potassium salt
- salt of alkaline earth metal such as magnesium salt, calcium salt and the like
- organic ammonium salt such as ammonium salt, triethyl ammonium salt, tributyl ammonium salt, pyridinium salt and the like
- salt of amino acid such as lysine salt, arginine salt and the like.
- Particularly preferred is sodium salt causing less toxicity in the living body.
- the fluorescent contrast agent to be used in a living body should be particularly water soluble.
- the near infrared fluorescent contrast agent has a noticeably improved water solubility by the introduction of 3 or more sulfonic acid groups into the above-mentioned compound.
- the number of the sulfonic acid groups is preferably 4 or more.
- the number of the sulfonic acid groups is not more than 10, preferably not more than 8.
- the improvement in the water solubility can be determined by measuring partition coefficient of each compound, which for example, may be measured in a two-phase system of butanol/water. More specifically, introduction of 3 or more sulfonic acid groups results in a partition coefficient log Po/w of n-butanol/water of not more than -1.00.
- the sulfonic acid groups are particularly preferably introduced into the positions of R 1 , R 2 , Z 1 and/or Z 2 of the formula [I] and R 1 , R 2 , R 5 , R 7 , R 11 and/or R 3 of the formula [II].
- these sulfonic acid groups are preferably introduced into L 4 of the conjugated methine chain at the position A of the above-mentioned formula (a) via a divalent group such as alkylene.
- sodium salts of compounds of the formula [II] having three or more sulfonic acid groups in a molecule preferred is a sodium salt of a compound wherein R 1 and R 2 are lower alkyl having 1 to 5 carbon atoms which is substituted by sulfonic acid group, and X and Y are the same or different and each is a group of the formula
- R 17 and R 18 are the same or different and each is unsubstituted lower alkyl having 1 to 5 carbon atoms alkyl, said salt having three or more sulfonic acid groups in a molecule, with particular preference given to a compound of the formula
- L 1 - L 7 are as defined above, R 19 and R 20 are lower alkyl having 1 to 5 carbon atoms which is substituted by sulfonic acid group, and R 21 to R 28 are the same or different and each is hydrogen atom, sulfonic acid group, carboxyl group, hydroxyl group, alkyl(sulfoalkyl)amino group, bis(sulfoalkyl)amino group, sulfoalkoxy group, (sulfoalkyl)sulfonyl group or (sulfoalkyl)amino- sulfonyl group, and X' and Y" are the same or different and each is a group of
- R 18 the formula wherein R 17 and R 18 are as defined above, said salt having three or more sulfonic acid groups in a molecule, with particular preference given to the compound of the following formula.
- sodium salts of the compounds of the formula [111-1] having three or more sulfonic acid groups in a molecule preferred is a sodium salt of a compound of the formula [III-2]
- the compounds contained in the inventive near infrared fluorescent contrast agent may be any as long as it has formula [I] or [II], as well as 3 or more, preferably 4 or more, sulfonic acid groups in a molecule.
- These compounds can be synthesized according to a known production method of cyanine dye compounds disclosed in The Cyanine Dyes and Related Compounds, F.M. Hamer, John Wiley and Sons, New York, 1964 , Cytometry, 10, 3-10 (1989), Cytometry, 11, 418-430 (1990), Cytometry, 12 723-730 (1990), Bioconjugate Chem. 4, 105-111 (1993), Anal.
- they can be semisynthesized from a commercially available cyanine dye compound by a known method.
- they can be synthesized by reacting a dianyl compound and a heterocyclic quaternary salt.
- the compound of the formula [I] of the present invention can be synthesized by, for example, the following method.
- T 1 - Na [VII] wherein T 1 is an organic acid residue are reacted to give a sodium salt of the compound of the above-mentioned formula [VI-1].
- a hetero ring quaternary salt compound (1 mole) of the above- mentioned formula [IV-1] and the above-mentioned dianyl compound (1 mole) of the formula [V-1] are reacted in the presence of a base and a solvent to give a compound of the formula [VI 11-1]
- a hetero ring quaternary salt compound (1 mole) of the above- mentioned formula [IV-1] and the above-mentioned dianyl compound (1 mole) of the formula [V-2] are reacted in the presence of a base and a solvent to give a compound of the formula [VIII-2]
- L 6 and L 7 overlap in the formula [I].
- L 2 , L 3 , L 4 , L 5 , L 6 and L 7 are as defined above and L 8 is an optionally substituted methine group, are reacted in the presence of a base and a solvent to give a compound of the formula [VI-3]
- a hetero ring quaternary salt compound (1 mole) of the above- mentioned formula [IV-1] and the above-mentioned dianyl compound (1 mole) of the formula [V-3] are reacted in the presence of a base and a solvent to give a compound of the formula [VIII-3]
- the necessary molar amount of the compound of the formula [VII] is not less than the amount equivalent to the amount of sodium contained in one molecule of the objective sodium salt of the compound of the formula [I].
- the substituent of the substituted methine group at L 8 and L 9 is exemplified by those mentioned with regard to the substituent of the above-mentioned methine groups at L 1 to L 7 .
- the base to be used may be, for example, triethylamine, tributylamine, pyridine, diazabicycloundecene, sodium methoxide and the like;
- the solvent to be used may be, for example, an amide compound such as N,N-dimethylacetamide, N- methylpyrrolidone and N,N-diethylformamide or alcohols such as methanol; and the organic acid residue may be, for example, CH 3 COO and the like.
- ammonium salt and potassium salt of the compounds of the formula [I] can be obtained by, for example, substituting the compound of the formula [VII] used in the above- mentioned synthetic methods (i), (ii) and (iii) with a compound of the formula [VII] wherein the sodium atom has been changed to ammonium group or potassium atom; and different cationic salts of the compounds of the aforementioned formula [I] can be obtained by converting said ammonium salt and potassium salt to different cationic salts by the use of ion exchange resins as necessary.
- the above-mentioned compound to be contained in the near infrared fluorescent contrast agent of the present invention shows absorbance and fluorescence in the near infrared light region of 700 - 1300 nm, particularly about 700 - 900 nm, and has a molar absorption coefficient of not less than 100,000.
- the near infrared fluorescent contrast agent of the present invention is subject to no particular limitation as long as it contains a compound of the formula [I] or formula [II] and/or a pharmaceutically acceptable salt thereof, and has 3 or more, preferably 4 or more, sulfonic acid groups in a molecule.
- This compound or a salt thereof alone or in combination may be contained in said contrast agent.
- said contrast agent includes said compound or said compound suspended or dissolved in a solvent, such as injectable distilled water, physiological saline, Ringer solution and the like.
- a solvent such as injectable distilled water, physiological saline, Ringer solution and the like.
- pharmacologically acceptable additives such as carrier, excipient and the like may be added.
- These additives contain substances such as pharmacologically acceptable electrolyte, buffer, detergent and a substance for adjusting osmotic pressure and improving stability and solubility (e.g., cyclodextrin, liposome and the like).
- Various additives generally used in the pertinent fields may be used.
- the near infrared fluorescent contrast agent of the present invention is preferably produced through a sterilization process when it is intended for pharmaceutical use.
- Said contrast agent can be administered to a living body by injecting, spraying or coating, intravascularly (venous, arterial), orally, intraperitoneally, percutaneously, subcutaneously, intracystically or intrabronchially.
- the agent is administered into blood vessels in the form of an aqueous agent, emulsion or suspension.
- the dose of the near infrared fluorescent contrast agent of the present invention is not particularly limited insofar as the dose enables detection of the site to be ultimately diagnosed. It is appropriately adjusted depending on the kind of compound to be used that emits near infrared fluorescence, age, body weight and target organ of administration subjects, and the like. Typically, the dose is 0.1 - 100 mg/kg body weight, preferably 0.5 - 20 mg/kg body weight, in the amount of said compound.
- the contrast agent of the present invention can be appropriately used for various animals other than human.
- the administration form, route and dose are suitably determined depending on the body weight and conditions of the target animals.
- the above-mentioned compound of the formula [I], particularly preferably [II], having 3 or more, preferably 4 or more, sulfonic acid groups in a molecule tends to be noticeably accumulated in tumor tissues.
- a tumor tissue can be specifically imaged using the inventive fluorescent contrast agent.
- a series of said compounds can reside in blood vessel for a long time and they are expected to serve well as angiography contrast agents.
- the fluorescence imaging method of the present invention is characterized by the use of the inventive near infrared fluorescent contrast agent.
- This method is practiced following known methods, and each parameter, such as excitation wavelength and fluorescence wavelength to be detected, is appropriately determined to achieve optimal imaging and evaluation, depending on the kind of near infrared fluorescent contrast agent to be administered and administration targets.
- the time spent from administration of the inventive near infrared fluorescent contrast agent to determination target to the initiation of determination by the inventive fluorescence imaging method varies depending on the kind of the near infrared fluorescent contrast agent to be used and administration targets. For example, when the agent contains a compound of the formula [I] for tumor imaging, the lapse time will be about 4- 120 hours after administration.
- the lapse time will be about 24-120 hours after administration.
- the fluorescence is so intense that the target site and other site cannot be clearly divided.
- said contrast agent may be cleared from the body.
- the compound of the formula [I] or formula [II] is detected immediately after administration or in about 30 minutes thereafter.
- the method typically includes the following steps.
- a near infrared fluorescent contrast agent of the present invention is administered to a detection target and the detection target is exposed to an excitation light from an excitation light source. Then, fluorescence from the near infrared fluorescent contrast agent, which has been caused by said excitation light, is detected with a fluorescence detector.
- the wavelength for excitation varies depending on the near infrared fluorescent contrast agent to be used. It is free of limitation as long as said compound efficiently emits fluorescence in the near infrared region. Preferably, a near infrared light having superior biotransmission capability is used.
- the wavelength of the near infrared fluorescence to be detected also varies depending on the contrast agent to be used.
- the excitation light source may be a conventional excitation light source, such as various lasers (e.g., ion laser, dye laser and semiconductor laser), halogen light source, xenon light source and the like.
- various optical filters may be used to obtain optimal excitation wavelength.
- fluorescence may be detected using various optical filters to pick up only fluorescence from said near infrared fluorescent contrast agent.
- the detected fluorescence is data-processed as fluorescence information and used to generate fluorescence images that can be recorded.
- the fluorescence images are generated by irradiating a wide area including the target tissue, detecting fluorescence with a CCD camera and image-processing the obtained fluorescence information.
- an optical CT device may be used, an endoscope may be used, or a fundus camera may be used.
- the fluorescence imaging method of the present invention enables visualizing systemic diseases, tumors, blood vessels and the like without damaging a living body.
- the present invention is explained in more detail by way of Examples and Experimental Examples, to which the present invention is not limited.
- the compound numbers in the following Examples and Experimental Examples correspond to those of the compounds explained by structural formulas.
- the compound wherein a symbol designating "potassium salt", “calcium salt” or “pyridinium salt” is indicated after the compound number (e.g. compound (29) K salt) means a compound that is the same as the compound expressed by the compound number (sodium salt) except that the counter ion is potassium salt, calcium salt or pyridinium salt instead of sodium salt.
- compound (31 )K salt means a compound that is the same as the compound (31 ) except that the counter ion is potassium instead of sodium
- compound (31 )Ca salt means a compound that is the same as compound (31 ) except that the counter ion is calcium instead of sodium
- compound (31 )pyridinium means a compound that is the same as compound (31 ) except that the counter ion is pyridinium instead of sodium.
- the following synthetic methods mostly consist of reactions of heterocyclic quaternary salt compound shown in Table 1 and dianyl compounds shown in Tables 2 and 3.
- heterocyclic quaternary salt compound Q1 (5 g) were added methanol (100 ml), N,N-dimethylformamide (25 ml), triethylamine (5.6 ml), dianyl compound A1 (1.83 g) and acetic anhydride (3 ml), and the mixture was stirred at room temperature for 4 hours. Triethyl amine (2.2 ml) and acetic anhydride (2 ml) were added, and the mixture was stirred at room temperature for 3 hours. The insoluble matter was filtered off, and a solution of sodium acetate (2 g) in methanol (15 ml) was added to the filtrate, which was followed by stirring at room temperature for 1 hour.
- heterocyclic quaternary salt compound Q2 (2.13 g) was added methanol (20 ml) and the mixture was cooled to 10°C. Thereto were added dianyl compound A2 (0.75 g), triethylamine (4 ml) and acetic anhydride (2 ml), and the mixture was stirred for 20 minutes. Acetic anhydride (2 ml) was added, and the mixture was stirred at 10 °C for 4 hours. The insoluble matter was filtered off, and a solution of sodium acetate (2 g) in a small amount of methanol was added to the filtrate. The resulting crystals were collected by filtration and washed with a small amount of methanol.
- heterocyclic quaternary salt compound Q3 (9.5 g) are added methanol (50 ml), triethylamine (7 ml), dianyl compound A3 (3.1 g) and acetic anhydride (3.9 ml), and the mixture is stirred at room temperature for 7 hours. The insoluble matter is filtered off, and a solution of sodium acetate (5 g) in a small amount of methanol is added to the filtrate. The mixture is stood overnight. The resulting crystals are collected by filtration and washed with a small amount of methanol. To the crystals is added water (30 ml) for dissolution. Sodium acetate (2 g) is added, and then methanol (30 ml) is added. The resulting crystals are collected by filtration, washed with a small amount of methanol and dried to give compound (6).
- heterocyclic quaternary salt compound Q3 (4.8 g) were added methanol (50 ml), triethylamine (4 ml), dianyl compound A4 (1.7 g) and acetic anhydride (2 ml), and the mixture was stirred at room temperature for 3 hours. The insoluble matter was filtered off, and a solution of sodium acetate (4 g) in a small amount of methanol was added to the filtrate. The resulting crystals were collected by filtration and washed with a small amount of methanol. To the crystals was added water (10 ml) for dissolution. Then methanol (10 ml) was added.
- heterocyclic quaternary salt compound Q3 (4.7 g) are added methanol (25 ml), triethylamine (2.8 ml), dianyl compound A5 (1.5 g) and acetic anhydride (2.4 ml), and the mixture is stirred at room temperature for 1 hour. Thereto are further added triethyl amine (3.5 ml) and acetic anhydride (1.5 ml), and the mixture is stirred at room temperature for 3.5 hours. The insoluble matter is filtered off, and a solution of sodium acetate (3 g) in a small amount of methanol is added to the filtrate. The mixture is stirred at room temperature for 1 hour.
- heterocyclic quaternary salt compound Q3 (3.75 g) were added methanol (25 ml), triethylamine (3.5 ml), dianyl compound A6 (1.95 g) and acetic anhydride (2.4 ml), and the mixture was stirred at room temperature for 1 hour. The insoluble matter was filtered off, and a solution of sodium acetate (3.9 g) in a small amount of methanol was added to the filtrate. The mixture was stirred at room temperature for 1 hour. The resulting crystals were collected by filtration and washed with a small amount of methanol. To the crystals was added water (10 ml) for dissolution.
- heterocyclic quaternary salt compound Q3 (3.5 g) are added methanol (20 ml), triethylamine (3.5 ml), dianyl compound A7 (1.2 g) and acetic anhydride (1.9 ml), and the mixture is stirred at room temperature for 10 hours, and then stood overnight. The mixture is stirred under heating at 50°C for 5 hours. Water (2 ml) is added and the insoluble matter is filtered off. A solution of sodium acetate (5 g) in a small amount of water is added to the filtrate. The mixture is stirred at room temperature for 30 minutes. The resulting crystals are collected by filtration and washed with a small amount of methanol and dried to give compound (4).
- heterocyclic quaternary salt compound Q4 (3.5 g) were added methanol (35 ml), triethylamine (3.5 ml) and acetic anhydride (2 ml), and dianyl comound A2 (1.8 g) was added portionwise with stirring. The mixture was further stirred for 1 hour. Acetic anhydride (2 ml) was added, and the mixture was stirred at room temperature for 5 hours. The insoluble matter was filtered off, and a solution of sodium acetate (4 g) in a small amount of methanol was added to the filtrate. The resulting crystals were collected by filtration and washed with a small amount of methanol. To the crystals was added water (10 ml) for dissolution.
- the infrared absorption spectrum was measured for the obtained compound (31 ) by potassium bromide tablet method using a Fourier transform infrared spectrometer (VALOR-III, manufactured by JASCO). The following peaks were detected. The spectrum is shown in Fig. 12. i
- heterocyclic quaternary salt compound Q1 (12 g) were added methanol (120 ml), triethylamine (13.6 ml), dianyl compound A8 (4.4 g) and acetic anhydride (2.4 ml), and the mixture was stirred for 30 minutes. Acetic anhydride (2.4 ml) was added and the mixture was stirred for 1.5 hours, and then acetic anhydride (2.4 ml) was added and the mixture was stirred at room temperature for 6 hours. Heterocyclic quaternary salt compound Q1 (1 g), triethyl amine (3 ml) and acetic anhydride (3 ml) were further added and the mixture was stirred at room temperature for 2 hours. The mixture was stood overnight.
- the compound (6) K salt (50 mg) was dissolved in a small amount of water and passed through an ion exchange resin to convert potassium of the compound (6) K salt to proton. Thereto was added methanol saturated with sodium acetate to allow precipitation of crystals. This procedure was repeated twice. The resulting crystals were collected by filtration, washed with a small amount of methanol and dried to give (32 mg) of compound (6). The obtained compound (6) showed yellow in a flame test.
- heterocyclic quaternary salt compound Q4 (3.5 g) were added methanol (20 ml), triethylamine (3.5 ml) and acetic anhydride (2 ml), and dianyl comound A1 (1.4 g) was added portionwise with stirring. The mixture was further stirred for 20 minutes. Acetic anhydride (1 ml) was added, and the mixture was stirred at room temperature for 1.5 hours. The insoluble matter was filtered off, and a solution of sodium acetate (4 g) in a small amount of methanol was added to the filtrate. The resulting crystals were collected by filtration and washed with a small amount of methanol. The crystals were dissolved in a small amount of water.
- the partition coefficient (log Po/w) of n-butanol/water was determined with respect to compound (29), compound (43), compound (45), compound (31 ), compound (3) K salt, compound (11 ) [available from Nippon Kankoh-Shikiso Kenkyusho CO., LTD. as NK-3261], compound (6) K salt, compound (2) K salt, compound (4) K salt, compound (34) and compound (54).
- NK-1967 Nippon Kankoh-Shikiso Kenkyusho CO., LTD.
- ICG Tokyo Kasei Kogyo
- mice Tumor tissue pieces of mouse colon carcinoma (colon 26 carcinoma) were subcutaneously grafted to the left breast of BALB/c nude mice (5 weeks old, Clea Japan, Inc.). Ten days later when the tumor grew to a diameter of about 8 mm, the mice were subjected to the test.
- a fluorescence excitation light source a titanium sapphire laser was used.
- the test mice were uniformly exposed to the laser light using a ring type light guide (Sumita Optical Glass Co.) wherein dispersion of irradiation was within 10%.
- the irradiation power output was adjusted so that it was about 40 ⁇ W/cm 2 near skin surface of the mice.
- the fluorescence was excited at the maximum excitation wavelength of each compound and fluorescence emission from the mice was detected and photographed through a short wavelength cutoff filter (IR84, IR86, IR88, Fuji Photo Film CO., LTD.) with a CCD camera (C4880, Hamamatsu Photonics K.K.).
- the cutoff filter was selected to fit the excitation wavelength of the compound.
- the exposure time was adjusted depending on the fluorescence intensity of each compound.
- test compounds used were compound (29), compound (31 ) and compound (6) K salt of the present invention, and NK-1967 and ICG having only 2 sulfonic acid groups in a molecule as control compounds.
- Each test compound (0.5 mg/ml) was dissolved in distilled water and administered to the mice via a tail vein. The dose was 5.0 mg/kg for compound (31 ), compound (6) K salt, NK-1967 and ICG, and 0.5 mg/kg for compound (29).
- the mice were anesthetized with diethyl ether and fluorescent light images of the entire body of the mice was photographed. The results are shown in Figs. 1 to 5.
- the compound (29) having a benzotricarbocyanine structure and six sulfonic acid groups, as well as compound (6) K salt and compound (31 ) both having a tricarbocyanine structure and four sulfonic acid groups obviously generated clearer images of tumor as compared to control compounds (NK-1967 having benzotricarbocyanine structure and ICG having tricarbocyanine structure) having two sulfonic acid groups.
- compound (29) could clearly depict the tumor even at a low dose and was noticeably effective.
- Nude mice were used for the test, compound (29) of the present invention and control compound ICG were intravenously injected from the tail vein at a dose of 5.0 mg/kg each under sevoflurane continuous inhalation anesthesia.
- intermittent photographing of the fluorescence images was initiated.
- exposure to excitation laser beam and extraction of fluorescence through a filter were done, wherein exposure time was one second.
- blood vessel was suitably imaged. The fluorescence images were photographed until 5 minutes after the administration.
- Figs. 6 to 9 show fluorescence images of the entire body of the mice at 20 seconds and 5 minutes after the administration.
- ICG failed to contrastively show blood vessel in 5 minutes, whereas compound (29) could image the blood vessel for longer time than ICG.
- tumor tissue pieces were grafted to CDFi mice (female, 5 weeks old, Japan SLC, Inc.), and about 2 weeks later when the tumor grew to a diameter of about 1 cm, the mice were subjected to the test.
- test compounds were compound (29) K salt and compound (41 ) K salt having a benzotricarbocyanine structure and 6 sulfonic acid groups; compound (6) K salt, compound (4) K salt, compound (45) K salt, compound (31 ), compound (31 ) K salt, compound (3) K salt, compound (2) K salt, compound (43) K salt and compound (11 ) having a tricarbocyanine structure and 4-5 sulfonic acid groups; and control compounds ICG and NK-1967.
- Each test compound was dissolved in distilled water (0.5 mg/ml) and used. The obtained each compound solution was administered from the tail vein of the mice (5.0 mg/kg). Blood was taken from the mice at 0.5, 1 , 4 and 24 hours after the administration of the compounds and centrifuged to give plasma.
- the fluorescence intensity of the plasma was measured by a spectrofluorescence meter (RF 5300 PC, SHIMADZU CORPORATION). A calibration curve of each compound was drawn and compound concentration in plasma was calculated. The results are shown in Fig. 10.
- the compounds of the present invention remained in plasma at high concentration for a long time.
- test compounds were those listed in Table 5.
- Each test compound was dissolved in distilled water to give a compound solution. This solution was intravenously injected to the conscious mice from the tail vein. The mice were monitored for 3 days after the administration, and acute toxicity [LD 50 (mg/kg body weight)] was estimated. The results are shown in Table 5.
- the near infrared fluorescent contrast agent of the present invention is excited by an excitation light and emits near infrared fluorescence. This infrared fluorescence is superior in transmission through biological tissues. Thus, detection of lesions in the deep part of a living body has been made possible.
- the inventive contrast agent is superior in water solubility and low toxic, and therefore, it can be used safely.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
Abstract
A near infrared fluorescent contrast agent comprising a compound having three or more sulfonic acid groups in a molecule, and a method of fluorescence imaging comprising introducing the near infrared fluorescent contrast agent of the present invention into a living body, exposing the body to an excitation light, and detecting near infrared fluorescence from the contrast agent. The near infrared fluorescent contrast agent of the present invention is excited by an excitation light and emits near infrared fluorescence. This infrared fluorescence is superior in transmission through biological tissues. Thus, detection of lesions in the deep part of a living body has been made possible. In addition, the inventive contrast agent is superior in water solubility and low toxic, and therefore, it can be used safely.
Description
NEAR INFRARED FLUORESCENT CONTRAST AGENT AND
FLUORESCENCE IMAGING
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a near infrared fluorescent contrast agent and fluorescence imaging using said contrast agent.
In treating diseases, it is vital to detect morphological and functional changes caused by the disease in the living body at an early stage of the disease. Especially when treating cancer, the site and size of tumor are significant determinant factors of the effective treatment design. Known methods for this purpose include biopsy by puncture and the like, and imaging diagnoses such as X-ray imaging, MRI, ultrasound imaging and the like. Biopsy is effective for definitive diagnosis, but at the same time it places great burden on test subjects and is not suitable for tracking time-course changes in lesions. X-ray imaging and MRI inevitably expose test subjects to radiation and magnetic waves. In addition, conventional imaging diagnoses as mentioned above require complicated operation and a long time for measurement and diagnosis. A large apparatus used for this purpose also makes it difficult to apply these methods during operation.
One of the image diagnoses is fluorescence imaging (Lipspn R. L. et al., J. Natl. Cancer Inst, 26, 1-11 (1961 )). This method uses, as a contrast agent, a substance that emits fluorescence upon exposure to an excitation light having a specific wavelength. Thus, a body is exposed to an excitation light from outside the body and the fluorescence emitted from the fluorescent contrast agent in the body is detected.
Such fluorescent contrast agent may be, for example, a porphyrin compound that accumulates in tumor and is used for photodynamic therapy (PDT), such as haematoporphyrin. Other examples include photophrin and benzoporphyrin
(see Lipspn R. L. et al., supra, Meng T. S. et al., SPIE, 1641, 90-98 (1992), WO 84/04665 and the like). These compounds are originally used for PDT and have phototoxicity, since this is what PDT requires. Consequently, these are not desirable diagnostic agents.
Meanwhile, retinal circulatory microangiography using a known fluorescent dye, such as fluorescein, fluorescamin and riboflabin, has been known (U.S. Patent No. 4945239). These fluorescent dyes emit fluorescence in a visible light region of 400-600 nm. In this region, the light transmission through living tissue is very low, so that the detection of lesions in the deep part of a body is nearly impossible.
In addition, the use, as fluorescent contrast agent, of cyanine compounds inclusive of indocyanine green (hereinafter to be abbreviated as ICG), which are used to determine liver function and cardiac output, has been documented (Haglund M. M. et al., Neurosurgery, 35, 930 (1994), Li, X. et al., SPIE, 2389, 789-797 (1995)). Cyanine compounds show absorbance in a near infrared light region (700-1300 nm).
Near infrared light shows high transmission through living tissues and can pass through a skull of about 10 cm in size. Because of this, it has been increasingly attracting attention in clinical medicine. For example, optical CT technique using optical transmission of medium has been drawing attention in the clinical field as a new technology. This is because near infrared light can pass through living body and can be used for monitoring oxygen concentration and circulation in the living body.
Cyanine compounds emit fluorescence in the near infrared region. The fluorescence in this region can pass through living tissues and offers the potential for a fluorescent contrast agent. Various cyanine compounds have been developed in recent years and tried as fluorescent contrast agents (W096/17628, WP97/13490 and the like). However, an agent having sufficient
solubility in water and safety to living body, as well as capability of distinguishing normal tissues from diseased tissues (selectivity for imaging target site), is not in existence.
SUMMARY OF THE INVENTION
It is therefore an object of the present invention to provide a fluorescent contrast agent. The inventive agent is low toxic and has a superior solubility in water. In addition, it emits fluorescence in a near infrared region that can pass through living tissues, and permits specific imaging of tumor and/or blood vessel.
Another object of the present invention is to provide a method of fluorescence imaging using said near infrared fluorescent contrast agent.
The present invention is predicated on the finding that introduction of three or more sulfonic acid groups into a cyanine dye compound results in the provision of a fluorescent contrast agent having a high solubility in water. It has been also found that a method of fluorescence imaging can be established when this contrast agent is used.
Thus, the present invention provides the following.
(1 ) A near infrared fluorescent contrast agent comprising a compound having three or more sulfonic acid groups in a molecule, which is represented by the formula [I]
X and Y are the same or different and each is a group of the formula
R3
— O — , — s — > — CH=CH — or — C —
wherein R3 and R4 are the same or different and each is substituted or unsubstituted alkyl, or a pharmaceutically acceptable salt thereof.
(2) The near infrared fluorescent contrast agent of (1 ) above, which is free of a carboxylic acid group in a molecule.
(3) The near infrared fluorescent contrast agent of (1 ) or (2) above, wherein, in the formula [I], r is 1.
(4) The near infrared fluorescent contrast agent of any of (1 ) to (3) above, wherein 4 or more sulfonic acid groups are contained in a molecule.
(5) The near infrared fluorescent contrast agent of any of (1 ) to (4) above, wherein 10 or less sulfonic acid groups are contained in a molecule.
(6) The near infrared fluorescent contrast agent of any of (1 ) to (4) above, wherein 8 or less sulfonic acid groups are contained in a molecule.
(7) The near infrared fluorescent contrast agent of any of (1 ) to (6) above, wherein the pharmaceutically acceptable salt is a sodium salt.
(8) The near infrared fluorescent contrast agent of any of (1 ) to (7) above, that is for tumor imaging and/or angiography.
(9) A sodium salt of a compound of the formula [II] having three or more sulfonic acid groups in a molecule
wherein R1, R2, L1 - L7 , X and Y are as defined above, and R5 to R16 are the same or different and each is a hydrogen atom, a sulfonic acid group, a carboxyl group, a hydroxyl group, an alkyl(sulfoalkyl)amino group, a bis(sulfoalkyl)amino group, a sulfoalkoxy group, a (sulfoalkyl)sulfonyl group or a (sulfoalkyl)aminosulfonyl group, exclusive of the groups of the following formulas
I I
CH3 CH,
(CH2)2CHS03 (CH2)2CHS03Na
I CH3 CH3
(CH2)2S03 (CH2)2S03Na
CH, CH,
(10) The sodium salt of (9) above, wherein, in the formula [II], R1 and R2 are each a lower alkyl having 1 to 5 carbon atoms substituted by a sulfonic acid
R 17
— C —
R1
group and X and Y are the same or different and each is a group of the formula wherein R 7 and R18 are unsubstituted lower alkyl having 1 to 5 carbon atoms. (11 ) The sodium salt of (10) above, having the formula
(CH2)4SO3 (CH2)4SO3Na
(12) A sodium salt of a compound of the formula [111-1] having three or more
— C —
R 18
sulfoalkoxy group, (sulfoalkyl)sulfonyl group or (sulfoalkyl)aminosulfonyl group, and X' and Y' are the same or different and each is a group of the formula wherein R17 and R18 are as defined above, exclusive of the groups of the following formulas
and
(13) The sodium salt of (12) above, wherein, in the formula [111-1], L is methine substituted by alkyl having 1 to 4 carbon atoms.
(14) The sodium salt of (12) above, which is a sodium salt of the compound of the formula [III-2] having three or more sulfonic acid groups in a molecule
wh
tom group necessary for forming a 5- or 6-membered ring and A is hydrogen atom
or a monovalent group.
(15) The sodium salt of (14) above, having the formula
(CH2)4SO3 (CH2)4SO3Na
(16) The sodium salt of (12) above, having the formula
(17) The sodium salt of any of (9), (10), (12), (13) and (14) above, comprising 4 or more sulfonic acid groups in a molecule.
(18) The sodium salt of any of (9), (10), (12), (13), (14) and (17) above, comprising 10 or less sulfonic acid groups in a molecule.
(19) The sodium salt of any of (9), (10), (12), (13), (14) and (17) above, comprising 8 or less sulfonic acid groups in a molecule.
(20) A near infrared fluorescent contrast agent comprising the sodium salt of any of (9) to (19) above.
(21 ) The near infrared fluorescent contrast agent of (20) above, which is for tumor imaging and/or angiography.
(22) A method of fluorescence imaging comprising introducing the near infrared fluorescent contrast agent of (1 ) above into a living body, exposing the body to an excitation light, and detecting near infrared fluorescence from the contrast agent.
(23) The sodium salt of (9) above, which is at least one member selected from the group consisting of the compounds of the following formulas
SO3Na
CH2CH2CHSO3 CH2CH2CHSO3Na
CH, CH,
(CH2)4SO, (CH2)4S03Na
(CH2)4S02 (CH2)4S03Na
SO,Na
(24) The sodium salt of (12) above, which is at least one member selected from the group consisting of the compounds of the following formulas
(CH2)2SO3 (CH2)2SO3Na
(CH2)4S03- (CH2)4S03Na
(CH2)4S03 " (CH2)4SQ3Na
(CH2)4S03 (CH2)4S03Na
(CH2)2S03 (CH2)7S03Na
(CH2)4SO3 (CH2)4SO3Na
(CH2)4SO3 (CH2)4SO3Na
(CH2)4SO, (CH2)4S03Na
NaOOC SO,Na
(CH2)3SO, (CH2)3S03Na
(CH2)3S03 (CH,)3S03Na
(CH2)4SO3 (CH2)4SO3Na
SC Na
(CH2)4SO3 ~ (CH2)4SO3Na
(CH2)4S03- (CH2)4S03Na
(CH2)4S03 (CH2)4S03Na
(CH2)4S03 (CH2)4S03Na
(CH2)4S03 (CH2)4S03Na
(CH2)4S03 (CH2)4S03Na
(CH2)4S03 (CH2)4S03Na
(CH2)4S03- (CH2)4S03Na and
(25) The near infrared fluorescent contrast agent of (1 ) above, comprising at
least one compound selected from the group consisting of the compounds of the following formulas
(CH2)4S03- (CH2)4S03Na
(CH2)4S03- (CH2)4S03Na
(CH2)4S03 (CH2)4S03Na
(CH2)2SO, (CH2)2S03Na
(CH2)3SO3 (CH2)3SO3Na
(CH2)3SO, (CH2)3S03Na
(CH2)4SO3 (CH2)4SO3Na
(CH2)4S03- (CH2)4S03Na
(CH2)4SO, (CH2)4S03Na
(CH2)4S03 (CH2)4S03Na
(CH2)4SO3 (CH2)4SO3Na
(CH2)4S03 (CH2)4S03H N(C2H5)3
(CH2)3SO, (CH2)3S03Na
(CH2)2S03 (CH2)2S03Na
(CH2)3SO3 (CH2)3SO3Na
CONHCH2CH2S03Na
(CH2)4S03 (CH2)4S03Na
(CH2)3S03 " (CH2)3S03Na
CH2CH2CHSO CH2CH2CHS03Na
CH, CH,
(CH2)4SO, (CH2)4SO3Na
NaOOC S03Na
(CH2)3SO, (CH2)3S03Na
(CH2)4SO, (CH,)4SO3Na
(CH2)4SO3 (CH2)4SO3Na
(CH2)4S03 (CH2)4S03Na
(CH2)2CHS03 (CH2)2CHS03Na
I
CH3 CH3
(CH2)2CHS03 " (CH2)2CHS03Na
I CH, CH,
(CH2)4S03 (CH2)4S03Na
(CH2)4S03- (CH2)4S03Na
(CH2)4S03 (CH2)4SQ3Na
(CH2)4S03 (CH2)4S03Na
(CH2)4S03 (CH2)4S03Na
(CH2)4S03 (CH2)4S03Na
and
(26) The sodium salt of (14) above, wherein the monovalent group of A is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, lower alkoxy, optionally substituted substituted amino, alkylcarbonyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted arylthio, cyano, nitro or halogen atom.
BRIEF DESCRIPTION OF THE DRAWINGS
Figs. 1 to 4 are photographs showing fluorescence imaging at 24 hours after administration of the compound, wherein administered were A:ICG (5 mg/kg), B:NK-1967 (5 mg/kg), C.compound (29) (0.5 mg/kg) and D:compound (6) K salt (5 mg/kg).
Fig. 5 is a photograph showing fluorescence imaging at 24 hours after administration of the compound, wherein administered was E:compound (31 ) (5 mg/kg).
Figs. 6 to 9 are photographs showing fluorescence imaging at 20 seconds and 5 minutes after administration of the compound (5 mg/kg), wherein administered were A.ICG (20 seconds later), B.ICG (5 minutes later), C.compound (29) (20 seconds later) and D:compound (29) (5 minutes later).
Fig. 10 is a graph showing the concentration of the compound in plasma at 0.5, 1 , 4 and 24 hours after administration of the compound, wherein the axis of
ordinates is concentration (μg/ml) of the compound in plasma at each time point.
Fig. 11 is a chart showing the infrared absorption spectrum of compound (29).
Fig. 12 is a chart showing the infrared absorption spectrum of compound (31 ).
Fig. 13 is a chart showing the infrared absorption spectrum of compound (6).
Fig. 14 is a chart showing the infrared absorption spectrum of compound (54).
DETAILED DESCRIPTION OF THE INVENTION
The terms used in the present specification are defined in the following.
The near infrared fluorescent contrast agent in the present invention means a contrast agent that emits fluorescence in a near infrared region.
In the present invention, the sulfonic acid group may mean sulfonate (-S03 " ) when said sulfonic acid group is used to form an inner salt. In the present invention, preferable X and Y are of the following formula
R3
wherein R3 and R4are the sa Tme or different and each is substituted or unsubstituted alkyl.
The alkyl of "substituted or unsubstituted alkyl" at R1, R2, R3 and R4 is preferably linear or branched lower alkyl having 1 to 5 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,
isopentyl, neopentyl, tert-pentyl, 2-methylpropyl, 1 ,1-dimethylpropyl and the like. The substituent may be, for example, sulfonic acid group, carboxyl, hydroxy and the like. Examples of substituted alkyl include hydroxymethyl, 1- hydroxyethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 4- hydroxybutyl, carboxymethyl, carboxyethyl, carboxybutyl, sulfomethyl, 2- sulfoethyl, 3-sulfopropyl, 4-sulfobutyl and the like. Preferred R1 and R2 are lower alkyl having 1 to 5 carbon atoms that is substituted by sulfonic acid group (e.g., 2-sulfoethyl, 3-sulfopropyl, 4-sulfobutyl and the like), and R3 and R4 are unsubstituted lower alkyl having 1 to 5 carbon atoms (e.g., methyl, ethyl and the like).
The unsubstituted lower alkyl having 1 to 5 carbon atoms at R17 and R18 is exemplified by those mentioned above with regard to the alkyl of "substituted or unsubstituted alkyl" at R1, R2, R3 and R4.
The alkyl group of the lower alkyl having 1 to 5 carbon atoms that is substituted by sulfonic acid group at R19 and R20 is exemplified by those mentioned above with regard to the alkyl of "substituted or unsubstituted alkyl" at R1, R2, R3 and R4, and examples of the substituted lower alkyl having 1 to 5 carbon atoms include 2-sulfoethyl, 3-sulfopropyl and 4-sulfobutyl.
The alkyl moiety of alkyl(sulfoalkyl)amino group, bis(sulfoalkyl)amino group, sulfoalkoxy group, (sulfoalkyl)sulfonyl group and (sulfoalkyl)aminosulfonyl group at R21 - R28 is preferably a linear or branched lower alkyl having 1 to 5 carbon atoms, which is exemplified by those mentioned above with regard to the alkyl of "substituted or unsubstituted alkyl" at R1, R2, R3 and R4.
In the present invention, the "nonmetallic atoms necessary for forming a substituted or unsubstituted condensed benzo ring or condensed naphtho ring" means a bonding group necessary for forming a condensed benzo ring or condensed naphtho ring, which is a group of the formula
When the condensed benzo ring or condensed naphtho ring has a substituent, said bonding group may include a substituent.
Specific examples thereof include carbon atom, nitrogen atom, oxygen atom, hydrogen atom, sulfur atom, halogen atom (e.g., fluorine atom, chlorine atom, bromine atom and iodine atom) and the like.
The substituent of the condensed benzo ring and condensed naphtho ring formed by the nonmetallic atoms at Z1 and Z2 is exemplified by sulfonic acid group, carboxyl, hydroxy, halogen atom (e.g., fluorine atom, chlorine atom, bromine atom and iodine atom), cyano, substituted amino (e.g., dimethylamino, diethylamino, ethyl 4-sulfobutylamino, di-(3-sulfopropyl)amino and the like), and substituted or unsubstituted alkyl as defined above, which is bonded to the ring directly or via a divalent bonding group. Preferable divalent bonding group may be, for example, -O-, -NHCO-, -NHS02-, -NHCOO-, - NHCONH-, -COO-, -CO-, SO2-, and the like. The alkyl of substituted or unsubstituted alkyl that is bonded to the ring directly or via a divalent connection group is exemplified preferably by methyl, ethyl, propyl and butyl, and the substituent is preferably exemplified by sulfonic acid group, carboxyl and hydroxy.
The substituent of methine at L1 - L7 is exemplified by substituted or unsubstituted alkyl (defined above), halogen atom (defined above), substituted or unsubstituted aryl, lower alkoxy and the like. The aryl of "substituted or unsubstituted aryl" is exemplified by phenyl, naphthyl and the like, preferably phenyl. Examples of the substituent include halogen atom (defined above, preferably chlorine atom) and the like. The substituted aryl includes, for
example, 4-chlorophenyl and the like. The lower alkoxy is preferably linear or branched alkoxy having 1 to 6 carbon atoms, which is specifically methoxy, ethoxy, propoxy, butoxy, tert-butoxy, pentyloxy and the like, preferably methoxy and ethoxy. In addition, the substituents of methine at L1 - L7 may be bonded each other to form a ring containing three methine groups, and this ring may further form a condensed ring with a ring containing different methine group. The ring containing three methine groups that is formed by the bonding of the substituents of methine at L1 - L7 is exemplified by 4,4-dimethylcyclohexene ring and the like.
The conjugated methine chain consisting of the groups of L1 - L7, and having a ring is preferably the group of the formula (a):
The "nonmetallic atoms necessary to form a 5- or 6-membered ring" is exemplified by those mentioned above.
In the formula (a) and [III-2] to be mentioned later, - or 6-membered ring at Z3 is exemplified by cyclopentene ring, cyclohexene ring, 4,4- dimethylcyclohexene ring and the like, with particular preference given to cyclopentene ring.
The monovalent group represented by A includes, for example, substituted or unsubstituted alkyl (defined above), substituted or unsubstituted aryl (defined above), substituted or unsubstituted aralkyl, lower alkoxy (defined above), substituted amino which is optionally substituted, alkylcarbonyloxy (e.g.,
acetoxy), substituted or unsubstituted alkylthio, substituted or unsubstituted arylthio, cyano, nitro, halogen atom (defined above), and the like. As used herein, aralkyl of the "substituted or unsubstituted aralkyl" is exemplified by benzyl, 2-phenylethyl, 1-phenylethyl, 3-phenylpropyl and the like, and the substituent may be sulfonic acid group, carboxyl, hydroxy, substituted or unsubstituted alkyl (defined above), alkoxy (defined above), halogen atom (defined above), and the like. The substituted amino of the "substituted amino which is optionally substituted" includes, for example, alkylamino (e.g., methylamino, ethylamino and the like), dialkylamino (dimethylamino, diethylamino and the like), diphenylamino, methylphenylamino, cyclic amino (e.g., morpholino, imidazolidino, ethoxycarbonylpiperadino and the like) and the like. The substituent with regard to the optional substitution of the "substituted amino which is optionally substituted" includes sulfonic acid group, carboxyl and the like. The alkylthio of the "substituted or unsubstituted alkylthio" may be, for example, methylthio, ethylthio and the like. Examples of the substituent include sulfonic acid group, carboxyl and the like. The arylthio of the "substituted or unsubstituted arylthio" is exemplified by phenylthio, naphthylthio and the like. Examples of the substituent include sulfonic acid group, carboxyl and the like.
The monovalent group represented by A is preferably fluorine atom, chlorine atom, dialkylamino (preferably having 6 or less carbon atoms, and optionally forming a ring) or morpholino. This group particularly preferably has a sulfonic acid group.
In the formula [I], r is preferably 1.
The pharmaceutically acceptable salt may be any as long as it forms a nontoxic salt with the compound of the formula [I]. Examples thereof include alkali metal salts such as sodium salt, potassium salt; salt of alkaline earth metal such as magnesium salt, calcium salt and the like; organic ammonium salt such as ammonium salt, triethyl ammonium salt, tributyl ammonium salt, pyridinium salt and the like; salt of amino acid such as lysine salt, arginine salt
and the like. Particularly preferred is sodium salt causing less toxicity in the living body.
The fluorescent contrast agent to be used in a living body should be particularly water soluble. In the present invention, the near infrared fluorescent contrast agent has a noticeably improved water solubility by the introduction of 3 or more sulfonic acid groups into the above-mentioned compound. For superior water solubility, the number of the sulfonic acid groups is preferably 4 or more. For easy synthesis, the number of the sulfonic acid groups is not more than 10, preferably not more than 8. The improvement in the water solubility can be determined by measuring partition coefficient of each compound, which for example, may be measured in a two-phase system of butanol/water. More specifically, introduction of 3 or more sulfonic acid groups results in a partition coefficient log Po/w of n-butanol/water of not more than -1.00.
The sulfonic acid groups are particularly preferably introduced into the positions of R1, R2, Z1 and/or Z2 of the formula [I] and R1, R2, R5, R7, R11 and/or R 3 of the formula [II].
In addition, these sulfonic acid groups are preferably introduced into L4 of the conjugated methine chain at the position A of the above-mentioned formula (a) via a divalent group such as alkylene.
Of the sodium salts of compounds of the formula [II] having three or more sulfonic acid groups in a molecule, preferred is a sodium salt of a compound wherein R1 and R2 are lower alkyl having 1 to 5 carbon atoms which is substituted by sulfonic acid group, and X and Y are the same or different and each is a group of the formula
R1 7 I
— c — I
R18
wherein R17 and R18 are the same or different and each is unsubstituted lower alkyl having 1 to 5 carbon atoms alkyl, said salt having three or more sulfonic acid groups in a molecule, with particular preference given to a compound of the formula
(CH2)4SO3 (CH2)4SO3Na
Of the compounds of the formula [I] having three or more sulfonic acid groups in a molecule and pharmaceutically acceptable salts thereof, preferred is a sodium salt of a compound of the formula [111-1]
wherein L1 - L7 are as defined above, R19 and R20 are lower alkyl having 1 to 5 carbon atoms which is substituted by sulfonic acid group, and R21 to R28 are the same or different and each is hydrogen atom, sulfonic acid group, carboxyl group, hydroxyl group, alkyl(sulfoalkyl)amino group, bis(sulfoalkyl)amino group, sulfoalkoxy group, (sulfoalkyl)sulfonyl group or (sulfoalkyl)amino- sulfonyl group, and X' and Y" are the same or different and each is a group of
R 17
— C —
R 18
the formula wherein R17 and R18 are as defined above, said salt having three or more sulfonic acid groups in a molecule, with particular preference given to the compound of the following formula.
(CH2)2S03 (CH2)2S03Na
Of the sodium salts of the compounds of the formula [111-1] having three or more sulfonic acid groups in a molecule, preferred is a sodium salt of a compound of the formula [III-2]
[111-2} wherein R19 - R28, X' and Y' are as defined above, Z3 is nonmetallic atoms necessary to form a 5- or 6-membered ring and A is hydrogen atom or a monovalent group, said salt having three or more sulfonic acid groups in a molecule, with particular preference given to the compound of the following formula
The compounds contained in the inventive near infrared fluorescent
contrast agent may be any as long as it has formula [I] or [II], as well as 3 or more, preferably 4 or more, sulfonic acid groups in a molecule. These compounds can be synthesized according to a known production method of cyanine dye compounds disclosed in The Cyanine Dyes and Related Compounds, F.M. Hamer, John Wiley and Sons, New York, 1964 , Cytometry, 10, 3-10 (1989), Cytometry, 11, 418-430 (1990), Cytometry, 12 723-730 (1990), Bioconjugate Chem. 4, 105-111 (1993), Anal. Biochem., 217, 197-204 (1994), Tetrahedron, 45, 4845-4866 (1989), EP-A-0591820A1 , EP-A- 0580145A1 , and the like. Alternatively, they can be semisynthesized from a commercially available cyanine dye compound by a known method. To be specific, they can be synthesized by reacting a dianyl compound and a heterocyclic quaternary salt.
The compound of the formula [I] of the present invention can be synthesized by, for example, the following method.
(i)when r=0
(a)L1=L5, X=Y, R1=R2 and Z1=Z2
A hetero ring quaternary salt compound (2 moles) of the formula [IV-1]
HC1 [v-i]
wherein L2, L3 and L4 are as defined above, are reacted in the presence of a base and a solvent to give a compound of the formula [VI-1]
wherein L1, L2, L3, L4, R1, Z1 and X are as defined above, and this compound
[VI-1] (1 mole) and a necessary molar amount of the compound of the formula
[VII]
T1 - Na [VII] wherein T1 is an organic acid residue, are reacted to give a sodium salt of the compound of the above-mentioned formula [VI-1].
(b) L1≠L5 or X≠Y or R1≠R2 or Z1≠Z2
A hetero ring quaternary salt compound (1 mole) of the above- mentioned formula [IV-1] and the above-mentioned dianyl compound (1 mole) of the formula [V-1] are reacted in the presence of a base and a solvent to give a compound of the formula [VI 11-1]
R1 wherein L1, L2, L3, L4, R1, Z1 and X are as defined above, and this compound
[VIII-1] (1 mole) and a hetero ring quaternary salt compound (1 mole) of the formula [XI-1]
R1 R^
wherein L1, L2, L3, L4, L5, R1, R2, Z1, Z2, X and Y are as defined above, and this compound of the formula [X-1] (1 mole) and a necessary molar amount of the above-mentioned compound of the formula [VII] are reacted to give a sodium salt of the compound of the above-mentioned formula [X-1].
(ii) when r=1
(a) L1=L7, X=Y, R1=R2 and Z1=Z2
A hetero ring quaternary salt compound (2 moles) of the formula [IV-1]
NH-L2=L3-L4=L5-L6=N HC1 [V-2]
wherein L , L , L , L and L are as defined above, are reacted in the presence of a base and a solvent to give a compound of the formula [VI-2]
L1=L2-L3=L4-L5=L6-L1 [VI-2]
R1 R1
wherein L1, L2, L3, L4, L5, L6, R1, Z1 and X are as defined above, and this compound [VI-2] (1 mole) and a necessary molar amount of the compound of the formula [VII]
T1 - Na [VII] wherein T1 is as defined above, are reacted to give a sodium salt of the compound of the above-mentioned formula [VI-2]. (b) L1≠L7 or X≠Y or R1≠R2 or Z1≠Z2
A hetero ring quaternary salt compound (1 mole) of the above- mentioned formula [IV-1] and the above-mentioned dianyl compound (1 mole) of the formula [V-2] are reacted in the presence of a base and a solvent to give a compound of the formula [VIII-2]
wherein L1, L2, L3, L4, L5, L6, R1, Z1 and X are as defined above, and this compound [VIII-2] (1 mole) and a hetero ring quaternary salt compound (1 mole) of the formula [IX-2]
wherein L7, Y, Z2 and R2 are as defined above, are reacted to give a compound of the formula [X-2]
When r is 2, L6 and L7 overlap in the formula [I]. To avoid this, the overlapping L6 and L7 are referred to as L8 and L9 for clarification, (a) L1=L9, X=Y, R1=R2 and Z1=Z2
A hetero ring quaternary salt compound (2 moles) of the formula
[IV-1]
wherein L2, L3, L4, L5, L6 and L7 are as defined above and L8 is an optionally substituted methine group, are reacted in the presence of a base and a solvent to give a compound of the formula [VI-3]
wherein L1, L2, L3, L4, L5, L6, L7, L8, R1, Z1 and X are as defined above, and this compound [VI-3] (1 mole) and a necessary molar amount of the compound of the formula [VII]
T1 - Na [VII] wherein T1 is as defined above, are reacted to give a sodium salt of the compound of the above-mentioned formula [VI-3]. (b) L1≠L9 or X≠Y or R1≠R2 or Z1≠Z2
A hetero ring quaternary salt compound (1 mole) of the above- mentioned formula [IV-1] and the above-mentioned dianyl compound (1 mole) of the formula [V-3] are reacted in the presence of a base and a solvent to give a compound of the formula [VIII-3]
wherein Y, Z2 and R2 are as defined above and L9 is an optionally substituted methine group, are reacted to give a compound of the formula [X-3]
R1 R2 [X-3]
wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, R1, R2, Z1, Z2X and Y are as defined above, and this compound of the formula [X-3] (1 mole) and a necessary molar amount of the above-mentioned compound of the formula [VII] are reacted to give a sodium salt of the compound of the above-mentioned formula [X-3].
The necessary molar amount of the compound of the formula [VII] is not less than the amount equivalent to the amount of sodium contained in one molecule of the objective sodium salt of the compound of the formula [I].
The substituent of the substituted methine group at L8 and L9 is exemplified by those mentioned with regard to the substituent of the above-mentioned methine groups at L1 to L7.
In the synthetic methods of the above-mentioned (i), (ii) and (iii), the reaction of
the compounds [IV-1] and [V-1], that of the compounds [VIII-1] and [XI-1], that of the compounds [IV-1] and [V-2], that of the compounds [VIII-2] and [IX-2], that of the compounds [IV-1] and [V-3] and that of the compounds [VIII-3] and [IX-3] proceed at a temperature of -20°C - 80°C, preferably -10°C - 40°C, preferably in the presence of an acylating agent such as acetic anhydride.
In the synthetic methods of the above-mentioned (i), (ii) and (iii), the reaction of the compounds [IV-1] and [VII], that of the compounds [X-1] and [VII], that of the compounds [VI-2] and [VII], that of the compounds [X-2] and [VII], that of the compounds [VI-3] and [VII] and that of the compounds [X-3] and [VII] proceed at a temperature of preferably 0°C - 40°C, preferably in the presence of a solvent such as alcohol and water.
In the synthetic methods of the above-mentioned (i), (ii) and (iii), the base to be used may be, for example, triethylamine, tributylamine, pyridine, diazabicycloundecene, sodium methoxide and the like; the solvent to be used may be, for example, an amide compound such as N,N-dimethylacetamide, N- methylpyrrolidone and N,N-diethylformamide or alcohols such as methanol; and the organic acid residue may be, for example, CH3COO and the like.
With regard to the production of various pharmaceutically acceptable salts of the compounds of the aforementioned formula [I], ammonium salt and potassium salt of the compounds of the formula [I] can be obtained by, for example, substituting the compound of the formula [VII] used in the above- mentioned synthetic methods (i), (ii) and (iii) with a compound of the formula [VII] wherein the sodium atom has been changed to ammonium group or potassium atom; and different cationic salts of the compounds of the aforementioned formula [I] can be obtained by converting said ammonium salt and potassium salt to different cationic salts by the use of ion exchange resins as necessary.
The compound of the above-mentioned formula [I] inclusive of the compound
of the formula [II] to be used in the present invention are specifically exemplified in the following, to which the present invention is not limited.
(CH2)2S03 (CH2)2S03Na
(CH2)4S03 (CH2)4S03Na
(CH2)2S03 (CH,)2S03Na
(CH2)3S03 (CH2)3S03Na
(CH2)4S03 (CH2)4S03Na
(U)
(15)
(CH2)4S03 (CH2)4SO,Na
(CH,)2S03 " (CH,)2S03Na
(19)
(CH2)4S03 (CH2)4S03Na
CH2S03Na
(22)
(23)
(24)
(CH2)3S03 (CH2)3S03Na
(CH,)4S03 ~ (CH2)4S03Na
(CH2)3S03 (CH2)3S03Na
(31)
I CH3 CH3
(34)
(CH2)2CHS03 (CH2)2CHS03Na
I
(35) I CH3 CH3
(36)
(CH2)2CHS03 " (CH2)2CHS03Na
CH3 CH,
(37)
(38)
(42)
(43)
(CH2)4S03 (CH2)4S03Na
(CH2)4S03 (CH2)4S03Na
(48)
(CH2)4S03 (CH2)4S03Na
(CH2)4S03 (CH2)4S03Na
(CH2)4S03 (CH2)4S03Na
(52)
(CH2)4S03 (CH2)4S03Na
(53)
(CH2)4SQ3- (CH2)4S03Na
(54)
The above-mentioned compound to be contained in the near infrared fluorescent contrast agent of the present invention shows absorbance and fluorescence in the near infrared light region of 700 - 1300 nm, particularly about 700 - 900 nm, and has a molar absorption coefficient of not less than 100,000.
The near infrared fluorescent contrast agent of the present invention is subject to no particular limitation as long as it contains a compound of the formula [I] or formula [II] and/or a pharmaceutically acceptable salt thereof, and has 3 or more, preferably 4 or more, sulfonic acid groups in a molecule. This compound or a salt thereof alone or in combination may be contained in said contrast agent.
To be specific, said contrast agent includes said compound or said compound suspended or dissolved in a solvent, such as injectable distilled water, physiological saline, Ringer solution and the like. Where necessary, pharmacologically acceptable additives such as carrier, excipient and the like
may be added. These additives contain substances such as pharmacologically acceptable electrolyte, buffer, detergent and a substance for adjusting osmotic pressure and improving stability and solubility (e.g., cyclodextrin, liposome and the like). Various additives generally used in the pertinent fields may be used. The near infrared fluorescent contrast agent of the present invention is preferably produced through a sterilization process when it is intended for pharmaceutical use.
Said contrast agent can be administered to a living body by injecting, spraying or coating, intravascularly (venous, arterial), orally, intraperitoneally, percutaneously, subcutaneously, intracystically or intrabronchially. Preferably, the agent is administered into blood vessels in the form of an aqueous agent, emulsion or suspension.
The dose of the near infrared fluorescent contrast agent of the present invention is not particularly limited insofar as the dose enables detection of the site to be ultimately diagnosed. It is appropriately adjusted depending on the kind of compound to be used that emits near infrared fluorescence, age, body weight and target organ of administration subjects, and the like. Typically, the dose is 0.1 - 100 mg/kg body weight, preferably 0.5 - 20 mg/kg body weight, in the amount of said compound.
The contrast agent of the present invention can be appropriately used for various animals other than human. The administration form, route and dose are suitably determined depending on the body weight and conditions of the target animals.
In the present invention, moreover, the above-mentioned compound of the formula [I], particularly preferably [II], having 3 or more, preferably 4 or more, sulfonic acid groups in a molecule tends to be noticeably accumulated in tumor tissues. Utilizing this characteristic, a tumor tissue can be specifically imaged using the inventive fluorescent contrast agent. In addition, a series of said
compounds can reside in blood vessel for a long time and they are expected to serve well as angiography contrast agents.
The fluorescence imaging method of the present invention is characterized by the use of the inventive near infrared fluorescent contrast agent. This method is practiced following known methods, and each parameter, such as excitation wavelength and fluorescence wavelength to be detected, is appropriately determined to achieve optimal imaging and evaluation, depending on the kind of near infrared fluorescent contrast agent to be administered and administration targets. The time spent from administration of the inventive near infrared fluorescent contrast agent to determination target to the initiation of determination by the inventive fluorescence imaging method varies depending on the kind of the near infrared fluorescent contrast agent to be used and administration targets. For example, when the agent contains a compound of the formula [I] for tumor imaging, the lapse time will be about 4- 120 hours after administration. In the case of compound of formula [II], the lapse time will be about 24-120 hours after administration. When the lapse time is too short, the fluorescence is so intense that the target site and other site cannot be clearly divided. When it is too long, said contrast agent may be cleared from the body. When imaging of blood vessel is desired, the compound of the formula [I] or formula [II] is detected immediately after administration or in about 30 minutes thereafter.
The method typically includes the following steps.
That is, a near infrared fluorescent contrast agent of the present invention is administered to a detection target and the detection target is exposed to an excitation light from an excitation light source. Then, fluorescence from the near infrared fluorescent contrast agent, which has been caused by said excitation light, is detected with a fluorescence detector.
The wavelength for excitation varies depending on the near infrared fluorescent contrast agent to be used. It is free of limitation as long as said
compound efficiently emits fluorescence in the near infrared region. Preferably, a near infrared light having superior biotransmission capability is used.
The wavelength of the near infrared fluorescence to be detected also varies depending on the contrast agent to be used. In general terms, an excitation light having a wavelength of 600-1000 nm, preferably 700-850 nm, is used and near infrared fluorescence in a region at a wavelength of 700-1000 nm, preferably 750-900 nm, is detected. In this case, the excitation light source may be a conventional excitation light source, such as various lasers (e.g., ion laser, dye laser and semiconductor laser), halogen light source, xenon light source and the like. Where necessary, various optical filters may be used to obtain optimal excitation wavelength. Likewise, fluorescence may be detected using various optical filters to pick up only fluorescence from said near infrared fluorescent contrast agent.
The detected fluorescence is data-processed as fluorescence information and used to generate fluorescence images that can be recorded. The fluorescence images are generated by irradiating a wide area including the target tissue, detecting fluorescence with a CCD camera and image-processing the obtained fluorescence information. Alternatively, an optical CT device may be used, an endoscope may be used, or a fundus camera may be used.
The fluorescence imaging method of the present invention enables visualizing systemic diseases, tumors, blood vessels and the like without damaging a living body.
The present invention is explained in more detail by way of Examples and Experimental Examples, to which the present invention is not limited. The compound numbers in the following Examples and Experimental Examples correspond to those of the compounds explained by structural formulas.
The compound wherein a symbol designating "potassium salt", "calcium salt" or "pyridinium salt" is indicated after the compound number (e.g. compound (29) K salt) means a compound that is the same as the compound expressed by the compound number (sodium salt) except that the counter ion is potassium salt, calcium salt or pyridinium salt instead of sodium salt. For example, "compound (31 )K salt" means a compound that is the same as the compound (31 ) except that the counter ion is potassium instead of sodium; "compound (31 )Ca salt" means a compound that is the same as compound (31 ) except that the counter ion is calcium instead of sodium; and "compound (31 )pyridinium" salt means a compound that is the same as compound (31 ) except that the counter ion is pyridinium instead of sodium.
The synthetic method of the compound to be contained in the near infrared fluorescent contrast agent of the present invention as an active ingredient is explained in Examples.
The following synthetic methods mostly consist of reactions of heterocyclic quaternary salt compound shown in Table 1 and dianyl compounds shown in Tables 2 and 3.
Table 1 Heterocyclic quaternary salt compound
(183272-36-8)
Table 2 Dianyl compound-1
In the following Examples, the compounds are referred to with the symbols (e.g., A1 , Q1 and the like) used in Tables 1 to 3 for the convenience's sake.
Example 1 : Synthesis of compound (29)
To heterocyclic quaternary salt compound Q1 (5 g) were added methanol (100 ml), N,N-dimethylformamide (25 ml), triethylamine (5.6 ml), dianyl compound A1 (1.83 g) and acetic anhydride (3 ml), and the mixture was stirred at room temperature for 4 hours. Triethyl amine (2.2 ml) and acetic anhydride (2 ml) were added, and the mixture was stirred at room temperature for 3 hours. The insoluble matter was filtered off, and a solution of sodium acetate (2 g) in methanol (15 ml) was added to the filtrate, which was followed by stirring at room temperature for 1 hour. The resulting crystals were collected by filtration and washed with a small amount of methanol. To the obtained crude crystals (3.5 g) was added water (20 ml) for dissolution. Sodium acetate (1 g) was added, and then methanol (30 ml) was added, which was followed by stirring for 1 hour. The resulting crystals were collected by filtration, washed with a small amount of methanol and dried to give 3 g of compound (29). The obtained compound (29) showed yellow in a flame test. Maximum wavelength of absorbance (H20) : 780 nm Molar absorption coefficient (H20) : 243,000 Maximum wavelength of fluorescence emission (H2O) : 802 nm
The infrared absorption spectrum was measured for the obtained compound (29) by potassium bromide tablet method using a Fourier transform infrared spectrometer (VALOR-III, manufactured by JASCO). The following peaks were detected. The spectrum is shown in Fig. 11. IR (Dmax(KBr)) : 1414, 1086, 1037, 995, 889 cm-1
Example 2 : Synthesis of compound (34)
To heterocyclic quaternary salt compound Q2 (2.13 g) was added methanol (20 ml) and the mixture was cooled to 10°C. Thereto were added dianyl
compound A2 (0.75 g), triethylamine (4 ml) and acetic anhydride (2 ml), and the mixture was stirred for 20 minutes. Acetic anhydride (2 ml) was added, and the mixture was stirred at 10 °C for 4 hours. The insoluble matter was filtered off, and a solution of sodium acetate (2 g) in a small amount of methanol was added to the filtrate. The resulting crystals were collected by filtration and washed with a small amount of methanol. To the obtained crude crystals was added water (7ml) for dissolution. Methanol (7 ml) was added to precipitate crystals. The resulting crystals were collected by filtration, washed with a small amount of methanol and dried to give 1.2 g of compound (34). The obtained compound (34) showed yellow in a flame test. Maximum wavelength of absorbance (H2O) : 794 nm Molar absorption coefficient (H2O) : 176,000 Maximum wavelength of fluorescence emission (H20) : 812 nm
Example 3 : Synthesis of compound (6)
To heterocyclic quaternary salt compound Q3 (9.5 g) are added methanol (50 ml), triethylamine (7 ml), dianyl compound A3 (3.1 g) and acetic anhydride (3.9 ml), and the mixture is stirred at room temperature for 7 hours. The insoluble matter is filtered off, and a solution of sodium acetate (5 g) in a small amount of methanol is added to the filtrate. The mixture is stood overnight. The resulting crystals are collected by filtration and washed with a small amount of methanol. To the crystals is added water (30 ml) for dissolution. Sodium acetate (2 g) is added, and then methanol (30 ml) is added. The resulting crystals are collected by filtration, washed with a small amount of methanol and dried to give compound (6).
Example 4 : Synthesis of compound (45)
To heterocyclic quaternary salt compound Q3 (4.8 g) were added methanol (50 ml), triethylamine (4 ml), dianyl compound A4 (1.7 g) and acetic anhydride (2 ml), and the mixture was stirred at room temperature for 3 hours. The insoluble matter was filtered off, and a solution of sodium acetate (4 g) in a small amount of methanol was added to the filtrate. The resulting crystals
were collected by filtration and washed with a small amount of methanol. To the crystals was added water (10 ml) for dissolution. Then methanol (10 ml) was added. The resulting crystals were collected by filtration, washed with a small amount of methanol and air dried to give 1.6 g of a compound that is the same as compound (45) except that the substituent on the methine chain is -Cl instead of -SCH2CH2S03 Na.
The above step was repeated to give 4.2 g of said compound. Thereto were added water (30 ml), triethylamine (1.2 ml) and sodium 2- mercaptoethanesulfonate (0.8 g), and the mixture was stirred at room temperature for 4 hours. The insoluble matter was filtered off, and a solution of sodium acetate (2 g) in a small amount of water was added to the filtrate. The resulting crystals were collected by filtration, washed with methanol (20 ml) and air dried to give 2.3 g of compound (45). The obtained compound (45) showed yellow in a flame test. Maximum wavelength of absorbance (H2O) : 815 nm Molar absorption coefficient (H2O) : 196,000 Maximum wavelength of fluorescence emission (H20) : 827 nm
Example 5 : Synthesis of compound (2)
To heterocyclic quaternary salt compound Q3 (4.7 g) are added methanol (25 ml), triethylamine (2.8 ml), dianyl compound A5 (1.5 g) and acetic anhydride (2.4 ml), and the mixture is stirred at room temperature for 1 hour. Thereto are further added triethyl amine (3.5 ml) and acetic anhydride (1.5 ml), and the mixture is stirred at room temperature for 3.5 hours. The insoluble matter is filtered off, and a solution of sodium acetate (3 g) in a small amount of methanol is added to the filtrate. The mixture is stirred at room temperature for 1 hour. The resulting crystals are collected by filtration and washed with a small amount of methanol. To the crystals is added water (15 ml) for dissolution. Then methanol (15 ml) is added. The resulting crystals are collected by filtration, washed with a small amount of methanol and dried to give compound (2).
Example 6 : Synthesis of compound (43)
To heterocyclic quaternary salt compound Q3 (3.75 g) were added methanol (25 ml), triethylamine (3.5 ml), dianyl compound A6 (1.95 g) and acetic anhydride (2.4 ml), and the mixture was stirred at room temperature for 1 hour. The insoluble matter was filtered off, and a solution of sodium acetate (3.9 g) in a small amount of methanol was added to the filtrate. The mixture was stirred at room temperature for 1 hour. The resulting crystals were collected by filtration and washed with a small amount of methanol. To the crystals was added water (10 ml) for dissolution. Sodium acetate (2 g) was added, and then methanol (10 ml) was added. The resulting crystals were collected by filtration, washed with a small amount of methanol and dried to give 1.8 g of compound (43). The obtained compound (43) showed yellow in a flame test. Maximum wavelength of absorbance (H20) : 773 nm Molar absorption coefficient (H20) : 204,000 Maximum wavelength of fluorescence emission (H20) : 789 nm
Example 7 : Synthesis of compound (4)
To heterocyclic quaternary salt compound Q3 (3.5 g) are added methanol (20 ml), triethylamine (3.5 ml), dianyl compound A7 (1.2 g) and acetic anhydride (1.9 ml), and the mixture is stirred at room temperature for 10 hours, and then stood overnight. The mixture is stirred under heating at 50°C for 5 hours. Water (2 ml) is added and the insoluble matter is filtered off. A solution of sodium acetate (5 g) in a small amount of water is added to the filtrate. The mixture is stirred at room temperature for 30 minutes. The resulting crystals are collected by filtration and washed with a small amount of methanol and dried to give compound (4).
Example 8 : Synthesis of compound (31)
To heterocyclic quaternary salt compound Q4 (3.5 g) were added methanol (35 ml), triethylamine (3.5 ml) and acetic anhydride (2 ml), and dianyl comound A2 (1.8 g) was added portionwise with stirring. The mixture was further stirred for 1 hour. Acetic anhydride (2 ml) was added, and the mixture was stirred at
room temperature for 5 hours. The insoluble matter was filtered off, and a solution of sodium acetate (4 g) in a small amount of methanol was added to the filtrate. The resulting crystals were collected by filtration and washed with a small amount of methanol. To the crystals was added water (10 ml) for dissolution. Then methanol (10 ml) was added, and the mixture was stirred at room temperature for 2 hours. The resulting crystals were collected by filtration, washed with a small amount of methanol and dried to give 1.3 g of compound (31 ). The obtained compound (31 ) showed yellow in a flame test. Maximum wavelength of absorbance (H20) : 755 nm Molar absorption coefficient (H20) : 228,000 Maximum wavelength of fluorescence emission (H20) : 774 nm
The infrared absorption spectrum was measured for the obtained compound (31 ) by potassium bromide tablet method using a Fourier transform infrared spectrometer (VALOR-III, manufactured by JASCO). The following peaks were detected. The spectrum is shown in Fig. 12. i
IR (vmax(KBr)) : 1518, 1183, 1149, 1111 , 995 cm-1
Example 9 : Synthesis of compound (41)
To heterocyclic quaternary salt compound Q1 (12 g) were added methanol (120 ml), triethylamine (13.6 ml), dianyl compound A8 (4.4 g) and acetic anhydride (2.4 ml), and the mixture was stirred for 30 minutes. Acetic anhydride (2.4 ml) was added and the mixture was stirred for 1.5 hours, and then acetic anhydride (2.4 ml) was added and the mixture was stirred at room temperature for 6 hours. Heterocyclic quaternary salt compound Q1 (1 g), triethyl amine (3 ml) and acetic anhydride (3 ml) were further added and the mixture was stirred at room temperature for 2 hours. The mixture was stood overnight. Sodium acetate (5 g) was added and the resulting crystals were collected by filtration and washed with a small amount of methanol. To the obtained crude crystals was added water (200 ml). The insoluble matter was filtered off, and sodium acetate (10 g) was added to the filtrate. The resulting crystals were collected by filtration and washed with a small amount of
methanol. To the crystals were added water (200 ml) and triethylamine (10 ml), and a solution of sodium acetate (10 g) in methanol (100 ml) was added to give crystals. This step was repeated twice. The resulting crystals were collected by filtration, washed with a small amount of methanol and dried to give 9.7 g of compound (41 ). The obtained compound (41 ) showed yellow in a flame test. Maximum wavelength of absorbance (H20) : 811 nm Molar absorption coefficient (H20) : 230,000 Maximum wavelength of fluorescence emission (H2O) : 822 nm
Example 10 : Synthesis of compound (3)
According to Example 5, heterocyclic quaternary salt compound Q3 and the corresponding dianyl compound are used to give compound (3).
Example 11
In the same manner as in the synthesis of compound (29) in Example 1 except that potassium acetate (2 g) was used instead of sodium acetate (2 g), a compound that is the same as compound (29) except that the counter ion was potassium instead of sodium was obtained. Hereinafter this compound is referred to as compound (29) K salt. The obtained compound (29) K salt showed purple in a flame test. Maximum wavelength of absorbance (H20) : 780 nm Molar absorption coefficient (H2O) : 254,000 Maximum wavelength of fluorescence emission (H2O) : 800 nm
Other aforementioned compounds are treated in the same manner as in this Example to give compounds having potassium counter ion instead of sodium.
These compounds having potassium counter ion are distinguished from the above compounds by attaching "K salt" after the corresponding compound numbers.
Example 12
In the same manner as in Example 11 , compound (6) K salt was obtained. The obtained compound (6) K salt showed purple in a flame test. Maximum wavelength of absorbance (H20) : 788 nm Molar absorption coefficient (H2O) : 226,000 Maximum wavelength of fluorescence emission (H20) : 806 nm
Example 13
In the same manner as in Example 11 , compound (2) K salt was obtained. The obtained compound (2) K salt showed purple in a flame test. Maximum wavelength of absorbance (H20) : 743 nm Molar absorption coefficient (H2O) : 266,000 Maximum wavelength of fluorescence emission (H20) : 762 nm
Example 14
In the same manner as in Example 11 , compound (4) K salt was obtained. The obtained compound (4) K salt showed purple in a flame test. Maximum wavelength of absorbance (H20) : 753 nm Molar absorption coefficient (H2O) : 212,000 Maximum wavelength of fluorescence emission (H20) : 767 nm
Example 15
In the same manner as in Example 11 , compound (3) K salt was obtained. The obtained compound (3) K salt showed purple in a flame test. Maximum wavelength of absorbance (H20) : 751 nm Molar absorption coefficient (H2O) : 241 ,000 Maximum wavelength of fluorescence emission (H20) : 767 nm
Example 16
The compound (6) K salt (50 mg) was dissolved in a small amount of water and passed through an ion exchange resin to convert potassium of the compound (6) K salt to proton. Thereto was added methanol saturated with
sodium acetate to allow precipitation of crystals. This procedure was repeated twice. The resulting crystals were collected by filtration, washed with a small amount of methanol and dried to give (32 mg) of compound (6). The obtained compound (6) showed yellow in a flame test.
The infrared absorption spectrum was measured for the obtained compound (6) by potassium bromide tablet method using a Fourier transform infrared spectrometer (VALOR-III, manufactured by JASCO). The following peaks were detected. The spectrum is shown in Fig. 13. IR (vmax(KBr)) : 1395, 1372, 1188, 1102, 1020 cm"1
Example 17 : Synthesis of compound (54)
To heterocyclic quaternary salt compound Q4 (3.5 g) were added methanol (20 ml), triethylamine (3.5 ml) and acetic anhydride (2 ml), and dianyl comound A1 (1.4 g) was added portionwise with stirring. The mixture was further stirred for 20 minutes. Acetic anhydride (1 ml) was added, and the mixture was stirred at room temperature for 1.5 hours. The insoluble matter was filtered off, and a solution of sodium acetate (4 g) in a small amount of methanol was added to the filtrate. The resulting crystals were collected by filtration and washed with a small amount of methanol. The crystals were dissolved in a small amount of water. Then the solution was diluted with methanol (10 ml), and the mixture was stirred at room temperature for 1 hour. The resulting crystals were collected by filtration, washed with a small amount of methanol and dried to give 1.5 g of compound (54). The obtained compound (54) showed yellow in a flame test. Maximum wavelength of absorbance (H2O) : 743 nm Molar absorption coefficient (H20) : 244,000 Maximum wavelength of fluorescence emission (H2O) : 766 nm
The infrared absorption spectrum was measured for the obtained compound (54) by potassium bromide tablet method using a Fourier transform infrared spectrometer (VALOR-III, manufactured by JASCO). The following peaks were
detected. The spectrum is shown in Fig. 14. IR (vmax(KBr)) : 1511 , 1421 , 1099, 1004, 926 cm"1
Experimental Example 1
The partition coefficient (log Po/w) of n-butanol/water was determined with respect to compound (29), compound (43), compound (45), compound (31 ), compound (3) K salt, compound (11 ) [available from Nippon Kankoh-Shikiso Kenkyusho CO., LTD. as NK-3261], compound (6) K salt, compound (2) K salt, compound (4) K salt, compound (34) and compound (54).
As a control compound, used were NK-1967 (Nippon Kankoh-Shikiso Kenkyusho CO., LTD.) and ICG (Tokyo Kasei Kogyo) having only 2 sulfonic acid groups in a molecule. The results are shown in Table 4.
Table 4
Tumor tissue pieces of mouse colon carcinoma (colon 26 carcinoma) were subcutaneously grafted to the left breast of BALB/c nude mice (5 weeks old, Clea Japan, Inc.). Ten days later when the tumor grew to a diameter of about 8 mm, the mice were subjected to the test.
As a fluorescence excitation light source, a titanium sapphire laser was used. The test mice were uniformly exposed to the laser light using a ring type light guide (Sumita Optical Glass Co.) wherein dispersion of irradiation was within 10%. The irradiation power output was adjusted so that it was about 40 μW/cm2 near skin surface of the mice. The fluorescence was excited at the maximum excitation wavelength of each compound and fluorescence emission from the mice was detected and photographed through a short wavelength cutoff filter (IR84, IR86, IR88, Fuji Photo Film CO., LTD.) with a CCD camera (C4880, Hamamatsu Photonics K.K.). The cutoff filter was selected to fit the excitation wavelength of the compound. The exposure time was adjusted depending on the fluorescence intensity of each compound.
The test compounds used were compound (29), compound (31 ) and compound (6) K salt of the present invention, and NK-1967 and ICG having only 2 sulfonic acid groups in a molecule as control compounds. Each test compound (0.5 mg/ml) was dissolved in distilled water and administered to the mice via a tail vein. The dose was 5.0 mg/kg for compound (31 ), compound (6) K salt, NK-1967 and ICG, and 0.5 mg/kg for compound (29). At 24 hours after the administration of the compouds, the mice were anesthetized with diethyl ether and fluorescent light images of the entire body of the mice was photographed. The results are shown in Figs. 1 to 5.
The compound (29) having a benzotricarbocyanine structure and six sulfonic acid groups, as well as compound (6) K salt and compound (31 ) both having a tricarbocyanine structure and four sulfonic acid groups obviously generated clearer images of tumor as compared to control compounds (NK-1967 having
benzotricarbocyanine structure and ICG having tricarbocyanine structure) having two sulfonic acid groups. In particular, compound (29) could clearly depict the tumor even at a low dose and was noticeably effective.
Experimental Example 3 : Fluorescence imaging test (2)
Nude mice were used for the test, compound (29) of the present invention and control compound ICG were intravenously injected from the tail vein at a dose of 5.0 mg/kg each under sevoflurane continuous inhalation anesthesia. At the same time, intermittent photographing of the fluorescence images was initiated. For photographing of the fluorescence images, exposure to excitation laser beam and extraction of fluorescence through a filter were done, wherein exposure time was one second. At 20 seconds after the administration of the compounds, blood vessel was suitably imaged. The fluorescence images were photographed until 5 minutes after the administration. Figs. 6 to 9 show fluorescence images of the entire body of the mice at 20 seconds and 5 minutes after the administration.
ICG failed to contrastively show blood vessel in 5 minutes, whereas compound (29) could image the blood vessel for longer time than ICG.
Experimental Example 4 : Residence in blood vessel
In the same manner as in Experimental Example 2, tumor tissue pieces were grafted to CDFi mice (female, 5 weeks old, Japan SLC, Inc.), and about 2 weeks later when the tumor grew to a diameter of about 1 cm, the mice were subjected to the test.
The test compounds were compound (29) K salt and compound (41 ) K salt having a benzotricarbocyanine structure and 6 sulfonic acid groups; compound (6) K salt, compound (4) K salt, compound (45) K salt, compound (31 ), compound (31 ) K salt, compound (3) K salt, compound (2) K salt, compound (43) K salt and compound (11 ) having a tricarbocyanine structure and 4-5 sulfonic acid groups; and control compounds ICG and NK-1967. Each test
compound was dissolved in distilled water (0.5 mg/ml) and used. The obtained each compound solution was administered from the tail vein of the mice (5.0 mg/kg). Blood was taken from the mice at 0.5, 1 , 4 and 24 hours after the administration of the compounds and centrifuged to give plasma.
The fluorescence intensity of the plasma was measured by a spectrofluorescence meter (RF 5300 PC, SHIMADZU CORPORATION). A calibration curve of each compound was drawn and compound concentration in plasma was calculated. The results are shown in Fig. 10.
The compounds of the present invention remained in plasma at high concentration for a long time.
Experimental Example 5 : Acute toxicity
Reduction of toxicity by the introduction of sulfonic acid group and reduction thereof by conversion into sodium salt were studied.
The test compounds were those listed in Table 5.
Each test compound was dissolved in distilled water to give a compound solution. This solution was intravenously injected to the conscious mice from the tail vein. The mice were monitored for 3 days after the administration, and acute toxicity [LD50 (mg/kg body weight)] was estimated. The results are shown in Table 5.
Table 5
An increase in the number of sulfonic acid group in a molecule or conversion to a sodium salt resulted in striking reduction of acute toxicity.
The near infrared fluorescent contrast agent of the present invention is excited by an excitation light and emits near infrared fluorescence. This infrared fluorescence is superior in transmission through biological tissues. Thus, detection of lesions in the deep part of a living body has been made possible. In addition, the inventive contrast agent is superior in water solubility and low toxic, and therefore, it can be used safely.
Claims
1. A near infrared fluorescent contrast agent comprising at least one compound selected from the group consisting of the compounds of the following formulas:
(30)
SOjNa
(CH2)4SO3 (CH2)4SO3Na 
2. A near infrared fluorescent contrast agent comprising the compound of the following formula:
3. A near infrared fluorescent contrast agent comprising the compound of the following formula:
4. A near infrared fluorescent contrast agent comprising the compound of the following formula:
(30)
5. A near infrared fluorescent contrast agent comprising the compound of the following formula:
(31)
6. A near infrared fluorescent contrast agent comprising the compound of the following formula:
7. A near infrared fluorescent contrast agent comprising the compound of the following formula:
(CH2)4SO3 (CH2)4SO3Na A near infrared fluorescent contrast agent comprising the compound of the following formula:
Priority Applications (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002394539A CA2394539C (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
| PL99355891A PL355891A1 (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
| BR9917587-8A BR9917587A (en) | 1999-12-15 | 1999-12-15 | Fluorescent contrast agent near infrared and fluorescence imaging |
| EA200200635A EA200200635A1 (en) | 1999-12-15 | 1999-12-15 | FLUORESCENT CONTRAST AGENT FOR NEAR INFRARED SPECTRUM AND METHOD OF FLUORESCENT VISUALIZATION |
| US10/149,917 US7547721B1 (en) | 1998-09-18 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
| IL14979899A IL149798A0 (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent |
| CN998170437A CN1217701C (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
| EP99965468A EP1237583A1 (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
| JP2001544917A JP2003517025A (en) | 1999-12-15 | 1999-12-15 | Near-infrared fluorescent contrast agent and fluorescence imaging |
| AU20975/00A AU2097500A (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
| KR1020027007635A KR20020082207A (en) | 1999-12-15 | 1999-12-15 | Near Infrared Fluorescent Contrast Agent and Fluorescence Imaging |
| MXPA02005806A MXPA02005806A (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging. |
| YU44402A YU44402A (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
| HU0204024A HUP0204024A2 (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
| SK814-2002A SK8142002A3 (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
| EEP200200321A EE200200321A (en) | 1999-12-15 | 1999-12-15 | Near-infrared fluorescence contrast agent and fluorescence imaging |
| TR2002/01567T TR200201567T2 (en) | 1999-12-15 | 1999-12-15 | Active fluorescent contrast agent and fluorescence imaging in the near infrared light region. |
| PCT/EP1999/009959 WO2001043781A1 (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
| BG106822A BG106822A (en) | 1999-12-15 | 2002-06-13 | Near infrared fluorescent contrast agent and fluorescence imaging |
| NO20022837A NO328630B1 (en) | 1999-12-15 | 2002-06-14 | Near infrared, fluorescent contrast agent and fluorescence imaging |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1999/009959 WO2001043781A1 (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2001043781A1 true WO2001043781A1 (en) | 2001-06-21 |
Family
ID=8167530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1999/009959 WO2001043781A1 (en) | 1998-09-18 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1237583A1 (en) |
| JP (1) | JP2003517025A (en) |
| KR (1) | KR20020082207A (en) |
| CN (1) | CN1217701C (en) |
| AU (1) | AU2097500A (en) |
| BG (1) | BG106822A (en) |
| BR (1) | BR9917587A (en) |
| CA (1) | CA2394539C (en) |
| EA (1) | EA200200635A1 (en) |
| EE (1) | EE200200321A (en) |
| HU (1) | HUP0204024A2 (en) |
| IL (1) | IL149798A0 (en) |
| MX (1) | MXPA02005806A (en) |
| NO (1) | NO328630B1 (en) |
| PL (1) | PL355891A1 (en) |
| SK (1) | SK8142002A3 (en) |
| TR (1) | TR200201567T2 (en) |
| WO (1) | WO2001043781A1 (en) |
| YU (1) | YU44402A (en) |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005061456A1 (en) * | 2003-12-19 | 2005-07-07 | Konica Minolta Medical & Graphic, Inc. | Near-infrared fluorescent contrast medium |
| WO2011025950A2 (en) | 2009-08-28 | 2011-03-03 | Visen Medical, Inc. | Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique |
| WO2011038006A1 (en) | 2009-09-22 | 2011-03-31 | Visen Medical, Inc. | Systems and methods for virtual index-matching of diffusive media |
| US8049184B2 (en) | 2007-01-18 | 2011-11-01 | Olympus Corporation | Fluoroscopic device and fluoroscopic method |
| WO2012001050A1 (en) | 2010-06-29 | 2012-01-05 | Ge Healthcare As | Dye compositions and dye syntheses |
| US8344158B2 (en) * | 2007-08-15 | 2013-01-01 | Washington University | Fluorescent polymethine cyanine dyes |
| WO2014062716A1 (en) | 2012-10-15 | 2014-04-24 | Visen Medical, Inc. | Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources |
| US8765961B2 (en) | 2009-08-28 | 2014-07-01 | Fujifilm Corporation | Near infrared fluorescent imaging agent |
| WO2015103420A1 (en) | 2013-12-31 | 2015-07-09 | Memorial Sloan Kettering Cancer Center | Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real time |
| CN105222828A (en) * | 2015-09-30 | 2016-01-06 | 东南大学 | The synchronous measuring apparatus of a kind of wall-jets velocity field and concentration field and method |
| WO2016100340A1 (en) | 2014-12-15 | 2016-06-23 | Memorial Sloan Kettering Cancer Center | Cyclic peptides with enhanced nerve-binding selectivity, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging |
| WO2016193396A1 (en) * | 2015-06-03 | 2016-12-08 | Surgimab S.A.S. | Fluorescent conjugates |
| WO2017106525A1 (en) | 2015-12-15 | 2017-06-22 | Memorial Sloan Kettering Cancer Center | Imaging systems and methods for tissue differentiation, e.g., for intraoperative visualization |
| US9782497B2 (en) | 2013-03-15 | 2017-10-10 | Purdue Research Foundation | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
| WO2018102372A1 (en) | 2016-11-30 | 2018-06-07 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
| US10806804B2 (en) | 2015-05-06 | 2020-10-20 | Washington University | Compounds having RD targeting motifs and methods of use thereof |
| US10904518B2 (en) | 2012-01-23 | 2021-01-26 | Washington University | Goggle imaging systems and methods |
| EP4015004A1 (en) | 2020-12-18 | 2022-06-22 | Phi Pharma SA | Proteoglycan specific branched peptides |
| US11406719B2 (en) | 2008-02-18 | 2022-08-09 | Washington University | Dichromic fluorescent compounds |
| US11712482B2 (en) | 2019-12-13 | 2023-08-01 | Washington University | Near infrared fluorescent dyes, formulations and related methods |
| US11989803B2 (en) | 2018-03-30 | 2024-05-21 | Perkinelmer Health Sciences, Inc. | Systems and methods for 3D reconstruction of anatomical organs and inclusions using short-wave infrared (SWIR) projection tomography |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005220045A (en) * | 2004-02-04 | 2005-08-18 | Konica Minolta Medical & Graphic Inc | Fluorescent contrast agent |
| US20130158394A1 (en) * | 2010-01-14 | 2013-06-20 | The Regents Of The University Of California | Devices, Systems and Methods to Detect and Reduce or Prevent Entry of Inflammatory Mediators into Milk Ducts |
| CN114459862A (en) * | 2022-01-13 | 2022-05-10 | 华腾实业（深圳）股份有限公司 | High-identification fungus fluorescent staining solution |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018006A1 (en) * | 1990-05-15 | 1991-11-28 | Diatron Corporation | Fluorescent porphyrin, and fluorescent phthalocyanine - polyethylene glycol, polyol, and saccharide derivatives as fluorescent probes |
| EP0800831A1 (en) * | 1995-01-30 | 1997-10-15 | Daiichi Pure Chemicals Co., Ltd. | Diagnostic marker |
| WO2000016810A1 (en) * | 1998-09-18 | 2000-03-30 | Schering Aktiengesellschaft | Near infrared fluorescent contrast agent and fluorescence imaging |
-
1999
- 1999-12-15 AU AU20975/00A patent/AU2097500A/en not_active Abandoned
- 1999-12-15 EP EP99965468A patent/EP1237583A1/en not_active Withdrawn
- 1999-12-15 WO PCT/EP1999/009959 patent/WO2001043781A1/en not_active Application Discontinuation
- 1999-12-15 JP JP2001544917A patent/JP2003517025A/en active Pending
- 1999-12-15 SK SK814-2002A patent/SK8142002A3/en unknown
- 1999-12-15 IL IL14979899A patent/IL149798A0/en not_active IP Right Cessation
- 1999-12-15 KR KR1020027007635A patent/KR20020082207A/en not_active Application Discontinuation
- 1999-12-15 CN CN998170437A patent/CN1217701C/en not_active Expired - Fee Related
- 1999-12-15 EE EEP200200321A patent/EE200200321A/en unknown
- 1999-12-15 PL PL99355891A patent/PL355891A1/en not_active Application Discontinuation
- 1999-12-15 CA CA002394539A patent/CA2394539C/en not_active Expired - Fee Related
- 1999-12-15 BR BR9917587-8A patent/BR9917587A/en not_active Application Discontinuation
- 1999-12-15 YU YU44402A patent/YU44402A/en unknown
- 1999-12-15 HU HU0204024A patent/HUP0204024A2/en unknown
- 1999-12-15 TR TR2002/01567T patent/TR200201567T2/en unknown
- 1999-12-15 MX MXPA02005806A patent/MXPA02005806A/en unknown
- 1999-12-15 EA EA200200635A patent/EA200200635A1/en unknown
-
2002
- 2002-06-13 BG BG106822A patent/BG106822A/en unknown
- 2002-06-14 NO NO20022837A patent/NO328630B1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018006A1 (en) * | 1990-05-15 | 1991-11-28 | Diatron Corporation | Fluorescent porphyrin, and fluorescent phthalocyanine - polyethylene glycol, polyol, and saccharide derivatives as fluorescent probes |
| EP0800831A1 (en) * | 1995-01-30 | 1997-10-15 | Daiichi Pure Chemicals Co., Ltd. | Diagnostic marker |
| WO2000016810A1 (en) * | 1998-09-18 | 2000-03-30 | Schering Aktiengesellschaft | Near infrared fluorescent contrast agent and fluorescence imaging |
Non-Patent Citations (1)
| Title |
|---|
| LICHA ET AL: "Synthesis and characterization of cyanine dyes as contrast agents for near-infrared imaging", PROCEEDINGS OF THE SPIE,US,SPIE, BELLINGHAM, VA, vol. 2927, 9 September 1996 (1996-09-09), pages 192 - 198, XP002079648 * |
Cited By (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005061456A1 (en) * | 2003-12-19 | 2005-07-07 | Konica Minolta Medical & Graphic, Inc. | Near-infrared fluorescent contrast medium |
| US8049184B2 (en) | 2007-01-18 | 2011-11-01 | Olympus Corporation | Fluoroscopic device and fluoroscopic method |
| US8344158B2 (en) * | 2007-08-15 | 2013-01-01 | Washington University | Fluorescent polymethine cyanine dyes |
| US11406719B2 (en) | 2008-02-18 | 2022-08-09 | Washington University | Dichromic fluorescent compounds |
| US8401618B2 (en) | 2009-08-28 | 2013-03-19 | Visen Medical, Inc. | Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique |
| WO2011025950A2 (en) | 2009-08-28 | 2011-03-03 | Visen Medical, Inc. | Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique |
| US8765961B2 (en) | 2009-08-28 | 2014-07-01 | Fujifilm Corporation | Near infrared fluorescent imaging agent |
| US8401619B2 (en) | 2009-09-22 | 2013-03-19 | Visen Medical, Inc. | Systems and methods for virtual index-matching of diffusive media |
| WO2011038006A1 (en) | 2009-09-22 | 2011-03-31 | Visen Medical, Inc. | Systems and methods for virtual index-matching of diffusive media |
| US9901254B2 (en) | 2009-09-22 | 2018-02-27 | Visen Medical, Inc. | Systems and methods for virtual index-matching of diffusive media |
| WO2012001050A1 (en) | 2010-06-29 | 2012-01-05 | Ge Healthcare As | Dye compositions and dye syntheses |
| US10904518B2 (en) | 2012-01-23 | 2021-01-26 | Washington University | Goggle imaging systems and methods |
| US11310485B2 (en) | 2012-01-23 | 2022-04-19 | Washington University | Goggle imaging systems and methods |
| US11765340B2 (en) | 2012-01-23 | 2023-09-19 | Washington University | Goggle imaging systems and methods |
| US10743768B2 (en) | 2012-10-15 | 2020-08-18 | Visen Medical, Inc. | Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources |
| US11903675B2 (en) | 2012-10-15 | 2024-02-20 | Visen Medical, Inc. | Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources |
| WO2014062716A1 (en) | 2012-10-15 | 2014-04-24 | Visen Medical, Inc. | Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources |
| US9782497B2 (en) | 2013-03-15 | 2017-10-10 | Purdue Research Foundation | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
| US9789208B2 (en) | 2013-03-15 | 2017-10-17 | Purdue Research Foundation | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
| WO2015103420A1 (en) | 2013-12-31 | 2015-07-09 | Memorial Sloan Kettering Cancer Center | Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real time |
| WO2016100340A1 (en) | 2014-12-15 | 2016-06-23 | Memorial Sloan Kettering Cancer Center | Cyclic peptides with enhanced nerve-binding selectivity, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging |
| US10940216B2 (en) | 2014-12-15 | 2021-03-09 | Cornell University | Cyclic peptides with enhanced nerve-binding selectively, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging |
| US10335501B2 (en) | 2014-12-15 | 2019-07-02 | Memorial Sloan Kettering Cancer Center | Cyclic peptides with enhanced nerve-binding selectively, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging |
| US11413359B2 (en) | 2015-05-06 | 2022-08-16 | Washington University | Compounds having RD targeting motifs and methods of use thereof |
| US10806804B2 (en) | 2015-05-06 | 2020-10-20 | Washington University | Compounds having RD targeting motifs and methods of use thereof |
| US9821079B2 (en) | 2015-06-03 | 2017-11-21 | Surgimab S.A.S. | Fluorescent conjugates |
| WO2016193396A1 (en) * | 2015-06-03 | 2016-12-08 | Surgimab S.A.S. | Fluorescent conjugates |
| AU2016271853B2 (en) * | 2015-06-03 | 2020-10-22 | Surgimab S.A.S. | Fluorescent conjugates |
| RU2720976C2 (en) * | 2015-06-03 | 2020-05-15 | Сюржимаб С.А.С. | Fluorescent conjugates and use thereof for tumor diagnostics |
| US10159757B2 (en) | 2015-06-03 | 2018-12-25 | Surgimab S.A.S. | Fluorescent conjugates |
| TWI702259B (en) | 2015-06-03 | 2020-08-21 | 法商瑟吉麥博股份公司 | Fluorescent conjugates |
| CN105222828A (en) * | 2015-09-30 | 2016-01-06 | 东南大学 | The synchronous measuring apparatus of a kind of wall-jets velocity field and concentration field and method |
| CN105222828B (en) * | 2015-09-30 | 2017-05-24 | 东南大学 | Synchronization measurement device for wall-adherent jet speed field and concentration field and method |
| WO2017106525A1 (en) | 2015-12-15 | 2017-06-22 | Memorial Sloan Kettering Cancer Center | Imaging systems and methods for tissue differentiation, e.g., for intraoperative visualization |
| WO2018102372A1 (en) | 2016-11-30 | 2018-06-07 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
| US11989803B2 (en) | 2018-03-30 | 2024-05-21 | Perkinelmer Health Sciences, Inc. | Systems and methods for 3D reconstruction of anatomical organs and inclusions using short-wave infrared (SWIR) projection tomography |
| US11712482B2 (en) | 2019-12-13 | 2023-08-01 | Washington University | Near infrared fluorescent dyes, formulations and related methods |
| WO2022129627A1 (en) | 2020-12-18 | 2022-06-23 | Phi Pharma Sa | Oligomeric compounds binding specifically to proteoglycans |
| EP4015004A1 (en) | 2020-12-18 | 2022-06-22 | Phi Pharma SA | Proteoglycan specific branched peptides |
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0204024A2 (en) | 2003-04-28 |
| PL355891A1 (en) | 2004-05-31 |
| BG106822A (en) | 2003-01-31 |
| CA2394539A1 (en) | 2001-06-21 |
| CN1384760A (en) | 2002-12-11 |
| NO20022837L (en) | 2002-06-14 |
| EP1237583A1 (en) | 2002-09-11 |
| SK8142002A3 (en) | 2002-12-03 |
| CA2394539C (en) | 2009-10-27 |
| YU44402A (en) | 2005-03-15 |
| BR9917587A (en) | 2002-08-06 |
| NO20022837D0 (en) | 2002-06-14 |
| KR20020082207A (en) | 2002-10-30 |
| EE200200321A (en) | 2003-10-15 |
| MXPA02005806A (en) | 2010-10-26 |
| CN1217701C (en) | 2005-09-07 |
| JP2003517025A (en) | 2003-05-20 |
| TR200201567T2 (en) | 2002-11-21 |
| EA200200635A1 (en) | 2002-12-26 |
| IL149798A0 (en) | 2002-11-10 |
| NO328630B1 (en) | 2010-04-12 |
| AU2097500A (en) | 2001-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1113822B1 (en) | Near infrared fluorescent contrast agent and fluorescence imaging | |
| CA2394539C (en) | Near infrared fluorescent contrast agent and fluorescence imaging | |
| US7547721B1 (en) | Near infrared fluorescent contrast agent and fluorescence imaging | |
| RU2350355C2 (en) | Fluorescent contrasting near infrared agent and method of fluorescent tomography | |
| CA2413033A1 (en) | Near infrared fluorescent contrast agent and fluorescence imaging | |
| US20030180221A1 (en) | Near infrared fluorescent contrast agent and fluorescence imaging | |
| JP3507060B2 (en) | Near-infrared fluorescent contrast agent and fluorescence imaging | |
| NZ525453A (en) | Near infrared fluorescent contrast agent useful for fluorescence imaging of tumour or in angiography | |
| CZ2001987A3 (en) | Fluorescent contrast agent emitting radiation in near infrared region and use of such agent ion fluorescence imaging process | |
| CZ20022092A3 (en) | Fluorescent contrast agent emitting radiation in near infrared region and use of such agent for fluorescent representation | |
| JP2005145819A (en) | Fluorescent contrast medium and method for in vitro fluorescence imaging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: P-444/02 Country of ref document: YU |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 149798 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2394539 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 519250 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1999965468 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 8142002 Country of ref document: SK |
|
| WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/00751/MU Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/A/2002/005806 Country of ref document: MX |
|
| ENP | Entry into the national phase |
Ref document number: 2001 544917 Country of ref document: JP Kind code of ref document: A Ref document number: 1999 106822 Country of ref document: BG Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002/01567 Country of ref document: TR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020027007635 Country of ref document: KR Ref document number: 20975/00 Country of ref document: AU Ref document number: PV2002-2092 Country of ref document: CZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 998170437 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200200635 Country of ref document: EA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200205571 Country of ref document: ZA |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999965468 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10149917 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020027007635 Country of ref document: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: PV2002-2092 Country of ref document: CZ |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1999965468 Country of ref document: EP |
|
| WWR | Wipo information: refused in national office |
Ref document number: 1020027007635 Country of ref document: KR |